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Background: Randomised controlled trials demonstrating improved longevity are needed to justify
high-dose vitamin D supplementation for older populations.
Objectives: To demonstrate the feasibility of a large trial (n ≈ 20,000) of high-dose vitamin D in people
aged 65–84 years through general practitioner (GP) practices, and to cluster randomise participating
practices between open-label and double-blind randomisation to compare effects on recruitment,
compliance and contamination.
Design: Twenty GP practices were randomised in matched pairs between open-label and double-blind
allocation. Within each practice, patients were individually randomised to vitamin D or control (i.e. no
treatment or placebo). Participants were invited to attend their GP practice to provide a blood sample and
complete a lifestyle questionnaire at recruitment and again at 2 years. Randomisation by telephone followed
receipt of a serum corrected calcium assay confirming eligibility (< 2.65 nmol/l). Treatment compliance was
reported by quarterly follow-up forms sent and returned by e-mail or post (participant choice). GP visits and
infections were abstracted from GP records. Hospital attendances, cancer diagnoses and deaths were
ascertained by linkage to Hospital Episode Statistics and national registration through NHS Digital.
Setting: GP practices in England.
Participants: Recruitment opened in October 2013 and closed in January 2015. A total of 1615 registered
patients aged 65–84 years were randomised: 407 to vitamin D and 421 to no treatment in open practices;
395 to vitamin D and 392 to placebo in blind practices.
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Interventions: There was a 24-month treatment period: 12 monthly doses (100,000 IU of vitamin D3
or placebo as 5 ml oily solution) were posted after randomisation and at 1 year (100,000 IU per month
corresponds to 3300 IU per day). Reminders were sent monthly by e-mail, text message or post.
Main outcome measures: Recruitment, compliance, contamination and change in circulating
25-hydroxyvitamin D [25(OH)D] from baseline to 2 years.
Results: Participation rates (randomised/invited) were 15.0% in open practices and 13.4% in double-blind
practices (p = 0.7). The proportion still taking study medication at 2 years was 91.2% in open practices and
89.2% in double-blind practices (p = 0.4). The proportion of control participants taking > 400 IU vitamin D
per day at 2 years was 5.0% in open practices and 4.8% in double-blind practices. Mean serum 25(OH)D
concentration was 51.5 nmol/l [95% confidence interval (CI) 50.2 to 52.8 nmol/l] with 82.6% of participants
< 75 nmol/l at baseline. At 2 years, this increased to 109.6 nmol/l (95% CI 107.1 to 112.1 nmol/l) with
12.0% < 75 nmol/l in those allocated to vitamin D and was unaltered at 51.8 nmol/l (95% CI 49.8 to
53.8 nmol/l) in those allocated to no vitamin D (no treatment or placebo).
Conclusions: A trial could recruit 20,000 participants aged 65–84 years through 200 GP practices over
2 years. Approximately 80% would be expected to adhere to allocated treatment (vitamin D or placebo)
for 5 years. The trial could be conducted entirely by e-mail in participants aged < 80 years, but some
participants aged 80–84 years would require postal follow-up. Recruitment and treatment compliance
would be similar and contamination (self-administration of vitamin D) would be minimal, whether control
participants are randomised openly to no treatment with no contact during the trial or randomised double-
blind to placebo with monthly reminders.
Trial registration: Current Controlled Trials ISRCTN46328341 and EudraCT database 2011-003699-34.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 10.
See the NIHR Journals Library website for further project information.
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Plain English summary
H igh-dose vitamin D may reduce the risk of many diseases, but without large randomised controlledtrials the evidence will remain inconclusive. We therefore proposed the Vitamin D and Longevity
(VIDAL) trial, with 20,000 older people randomised to either no vitamin D medication or vitamin D
medication for 5 years. The VIDAL feasibility study was conducted to establish the procedures required
for the main trial, including assessment of recruitment, compliance (taking study treatment as directed)
and contamination (how many control participants started taking vitamin D). This was done in two sets
of general practitioner (GP) practices: (1) ‘open’ practices, in which participants knew their treatment
allocation (2 years of 100,000 IU vitamin D monthly or no treatment), and (2) ‘double-blind’ practices,
in which participants and their GPs did not know whether they were taking vitamin D or placebo oil.
We invited 11,376 men and women aged 65–84 years from 20 GP practices in England and 1615 (14%)
took part. Ninety per cent of participants allocated to monthly oil took it for 2 years and few participants
used vitamin supplements outside the trial, with no marked differences between open-label and double-blind
arms. The best way to conduct the main trial will therefore depend on other considerations. A double-blind
trial provides reliable evidence on effects where reporting could be influenced by you or your doctor knowing
your treatment, which is important for many illnesses and any side effects of treatment. However, any
long-term effects are likely to be considerably greater if treatment continues instead of stopping after 5 years
when the main trial ends. An open trial is easier to conduct and, when it ends, those taking vitamin D can be
offered a continuing supply so that the effect of lifelong treatment can be studied for major diseases and life
expectancy, which are unlikely to be affected by individuals knowing whether or not they are taking vitamin D.
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Scientific summary
Background
There is strong but not conclusive evidence that serum 25-hydroxyvitamin D [25(OH)D] should be at least
75 nmol/l for optimal health. Neither the vitamin D reference nutrient intake (400 IU per day) nor the
increased consumption of foods containing vitamin D will raise the majority of the UK population aged
> 65 years above this level. Plausible effects of vitamin D deficiency include premature death and increased
risks of pneumonia, cardiovascular disease, some cancers, dementia, falls and fractures. We therefore
proposed the Vitamin D and Longevity (VIDAL) trial, a large randomised controlled trial of high-dose
monthly vitamin D3 for 5 years with all-cause mortality as the primary end point (20,000 participants aged
65–84 years at entry). The VIDAL feasibility study was conducted to assess the feasibility of that larger
main trial.
Objectives
The primary objectives were to assess feasibility by randomising 1600 individuals aged 65–84 years through
20 participating general practitioner (GP) practices and to estimate the effects of trial design (open-label vs.
double-blind randomisation) on recruitment, compliance and contamination. This was done by randomising
the 20 practices in matched pairs between open allocation [randomising between an open-label vitamin D
(OD) arm and an untreated open control (OC) arm] and double-blind allocation [randomising between a
blind vitamin D (BD) arm and a blind placebo control (BC) arm].
Methods
Eligibility
Registered patients were considered for inclusion if they were aged 65–84 years and were willing to be
randomised, were contactable by telephone, were able to receive recorded delivery post, were able to attend
enrolment at the GP surgery and had GP notes available for the previous year. Exclusion criteria were:
l active tuberculosis, sarcoidosis, hyperparathyroidism, past or present nephrolithiasis, vitamin D intolerance,
suspected hepatic or renal dysfunction, terminal illness, any malignancy other than non-melanoma skin
cancer not in remission for ≥ 3 years, or any other condition that the GP or clinical principal investigator
believed might compromise trial participation
l corrected serum calcium concentration of > 2.65 mmol/l
l taking dietary supplements or other medication containing > 400 IU (10 μg) per day of vitamin D
l concomitant therapy with carbamazepine, phenobarbital, phenytoin, primidone, digoxin, oral
1-alpha-hydroxylated vitamin D preparations (e.g. alfalcalcidol, calcitriol) or the combination of
a thiazide diuretic (e.g. bendrofluazide, metolazone) with a calcium supplement
l treatment with any other investigational medical product or device up to 4 months before the first
dose of investigational medicinal product.
Cluster randomisation of practices
The 20 participating GP practices were cluster randomised to open-label or double-blind individual
randomisation within pairs matched approximately on size, whether urban or rural, ethnic mix and
ward multiple deprivation index based on practice postcode.
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Recruitment
After compiling a list of registered patients aged 65–84 years and excluding any who were deemed
ineligible, the practice staff sent patient information booklets and invitations in batches by post.
No reminders were sent. Those who responded were invited to attend their practice to verify eligibility,
give written informed consent, have their blood pressure (BP) and body mass index (BMI) recorded,
complete a short lifestyle questionnaire and provide a blood sample for calcium and 25(OH)D assay.
The web-based clinical data management system: the VIDAL online application
Participating practices accessed the VIDAL app (online application) during the baseline visit to create a
participant record and enter identifying information and questionnaire responses when the informed
consent documentation had been signed, and throughout the trial to update their records. The trials office
accessed the VIDAL app to randomise participants and to manage and monitor study progress. The app
sent monthly reminders to take medication (by automated telephone call, e-mail and/or text message).
Quarterly questionnaires were either sent and received automatically by e-mail or printed and sent by post.
Randomisation, treatment and follow-up
When a corrected calcium result confirming eligibility (< 2.65 nmol/l) was received, the participant was
telephoned by the trials office to confirm willingness to participate and was then immediately randomised
by the VIDAL app. Participants allocated to study medication (BD, BC or OD arms) were sent 12 monthly
doses of 100,000 IU (2.5 mg) vitamin D3 or placebo in 5 ml oily solution by recorded delivery post
immediately following randomisation and 1 year later. They received monthly reminders to take the study
medication and 3-monthly questionnaires on treatment compliance, additional vitamin D intake (prescribed
or self-administered) and adverse events. Apart from 121 participants who were telephoned in 2014 for
an interim report (see Contamination in open and placebo control participants), OC participants were not
re-contacted until 2 years later, when all participants were invited to attend their practice for repeat
measurement of BP and BMI, blood sampling and the same lifestyle questionnaire. All participants were
traced through Hospital Episode Statistics (HES) for hospital admissions and through national registers for
cancer diagnoses and deaths. At the end of the trial, GP records of practice visits, diagnoses and prescriptions
for the 2 years of the trial and the preceding year were downloaded and all baseline and follow-up serum
samples were retrieved for 25(OH)D assay.
Results
There were 11,376 potential participants invited; 1673 participants attended the baseline visit and
1615 were randomised (target 1600). The participation rate (number randomised/number invited) was
higher in open practices (15.0%, range 8.8–22.4%) than in blind practices (13.4%, range 7.7–26.4%),
but this difference did not approach statistical significance owing to the wide variation between practices
(Wilcoxon signed-rank test; p = 0.7). Of the randomised participants, 53.1% were male and virtually all
(99.1%) were white. The overall participation rate of 14.2% (target 9%) was higher at age 65–79 years
(14.6%: 1459/10,018) than at 80–84 years (11.5%: 156/1358). The percentage in each age group
choosing e-mail rather than post for receiving and returning quarterly follow-up forms was 77.4% (483/624),
67.6% (345/510), 55.7% (181/325) and 36.5% (57/156) at ages 65–69, 70–74, 75–79 and 80–84 years,
respectively, and was 55.7% (477/857) for men and 47.4% (359/758) for women. The numbers randomised
were 395 to BD and 392 to BC in the 10 double-blind practices, and 407 to OD and 421 to untreated OC
in the 10 open practices.
Mortality and serious adverse events
The trial was not powered to detect clinical effects or mortality differences. The number of deaths by
allocated treatment was as follows: four (OC), eight (OD), three (BC) and five (BD). The numbers of
serious adverse events (SAEs) reported (none of which was judged to be associated with treatment) were
13 (OC – SAEs not reported during trial), 48 (OD), 45 (BC) and 46 (BD). Emergency hospital admission was
recorded in HES for 52 (OC), 47 (OD), 44 (BC) and 48 (BD) participants.
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Compliance among participants allocated to study medication
Among participants allocated to study medication (BD, BC or OD), the proportion who were still taking
allocated treatment declined from 95.7% at 6 months to 89.8% at 2 years. The proportion of surviving
participants who attended the 2-year follow-up was similar for OD (93.2%) and blind practices (92.6%).
Contamination among open and placebo control participants
To obtain information on vitamin D consumption for an interim report, 121 participants randomised to
no treatment in open practices (OC) before May 2014 were contacted by post, e-mail or telephone in
December 2014. There was no other contact after randomisation with OC participants until they were
invited to attend the 2-year final visit.
Information on vitamin D consumption at 2 years was obtained from 400 (95.9%) of the 417 OC survivors:
366 (87.8%) who attended the 2-year visit and a further 34 who were interviewed at 2 years by telephone
but did not attend. Only 20 (5.0%) were taking > 400 IU of vitamin D per day (11 prescribed by the GP and
nine self-administered), compared with 4.8% of placebo control participants in blind practices.
Baseline 25(OH)D levels
The mean baseline 25(OH)D level was higher in men [54.2 nmol/l, 95% confidence interval (CI) 52.3 to
56.1 nmol/l] than in women (48.5 nmol/l, 95% CI 46.6 to 50.3 nmol/l). The level was significantly
associated with every variable except age and use of sun protection in a multivariate regression including
sex, age, season, skin complexion, consumption of oily fish, travel abroad in last year, quality of life (QoL),
latitude of practice, deprivation quintile, time outdoors, actively seeking suntan, sunbed use and use of sun
protection (adjusted p-values: sex 0.003, age 0.6, deprivation 0.04, sun protection 0.3, sunbed use 0.02,
all other variables ≤ 0.001).
Infections
The proportion of participants with two or more infections recorded in GP records during the trial was 10.2%
in the control arms (OC and BC) and slightly but not significantly lower, at 9.1%, in the vitamin D arms (OD
and BD). Among those with a baseline 25(OH)D of < 25 nmol/l, these proportions were 16.9% (control arms)
and 9.8% (vitamin D arms), which was still a non-significant difference.
Change in 25(OH)D from baseline to 2-year follow-up
A similar and highly significant (p < 0.0001) effect of treatment on 25(OH)D levels was seen in both open
and blind practices. At the 2-year visit, the mean 25(OH)D level and percentage of participants < 75 nmol/l
by allocated treatment were 109.2 nmol/l and 11.0% (BD), 50.6 nmol/l and 83.1% (BC), 110.0 nmol/l
and 13.0% (OD), and 53.0 nmol/l and 81.0% (OC). The increases over baseline in the mean level were
58.6 nmol/l in the blind practices and 58.0 nmol/l in the open practices, and the reductions in the
percentage < 75 nmol/l were 72.1% and 68.0%, respectively. The percentage who were suboptimal
[25(OH)D of < 75 nmol/l] declined from 83.6% at baseline to 12.1% at 2 years in those allocated to
vitamin D and was unchanged at 81.9% in control participants (placebo or no treatment).
Conclusions
Recruitment and compliance were high and contamination in control participants was low, with no marked
differences between open and blind practices. This confirms the feasibility of conducting the main trial with
either open-label or double-blind randomisation (20,000 recruited through 200 GP practices with equal
numbers at each age from 65 to 84 years).
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Recommendations for research
1. The main trial should be conducted, as it would constitute a major and perhaps decisive addition to the
worldwide evidence on what the UK vitamin D reference nutrient intake should be for those aged
≥ 65 years.
2. The National Institute for Health Research (NIHR) Health Technology Assessment (HTA), in consultation with
the relevant agencies, should review opportunities for reducing delays in Clinical Research Network funding
approvals for multicentre population-based prophylactic trials, and for simplifying trial regulations for
non-prescription treatments such as vitamin D for which extensive evidence on safety is already available.
3. Reports published after this trial began suggest that the treatment tested should be ≈4000 IU vitamin D
daily rather than the monthly regimen we used.
Trial registration
This trial is registered as ISRCTN46328341 and EudraCT database 2011-003699-34.
Funding
This project was funded by the National Institute for Health Research Health Technology Assessment
programme and will be published in full in Health Technology Assessment; Vol. 24, No. 10. See the
NIHR Journals Library website for further project information.
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Chapter 1 Introduction
The number of people aged ≥ 80 years in the UK is projected to more than double, to 6 million, by mid-2037,1 and interventions that improve quality as well as length of life are needed.2 Cancer, cardiovascular
disease, dementia, community-acquired pneumonia, falls and fractures account for much of the reduction in
the quality of life (QoL) as well as overall mortality rates of older adults3–7 and impose a huge economic
burden on the NHS, social services and many families.8 There is, therefore, a need for new interventions to
prevent these conditions. A large and growing body of evidence identifies vitamin D supplementation as a
promising candidate to reduce morbidity and mortality in the elderly.9 Vitamin D is a pre-pro-hormone that is
synthesised in the skin by ultraviolet B radiation in sunlight, which is a major source of vitamin D. Dietary
sources are limited, with oily fish being the only significant contributor.10 At the UK’s latitude (50–58°N),
sunlight can stimulate cutaneous vitamin D synthesis only between April and October.11 Consequently,
vitamin D insufficiency {defined as a serum 25-hydroxyvitamin D [25(OH)D] concentration of < 75 nmol/l} is
very common, especially among older adults, who may spend less time outdoors and whose skin is less
efficient at synthesising vitamin D.9 Vitamin D insufficiency among older adults in the UK may therefore be an
important and readily correctable risk factor for a variety of diseases. Offering a daily vitamin D supplement to
all UK adults aged > 65 years would be inexpensive and safe and could result in significant and cost-effective
improvements in QoL as well as longevity.
The diversity of the roles played by vitamin D in normal human physiology offers a plausible explanation of
how a single micronutrient might ameliorate a heterogeneous collection of diseases. Humans evolved at
equatorial latitudes in unlimited sunshine, and serum concentrations of the major circulating metabolite,
25(OH)D, are ≈115 nmol/l in people living traditional lifestyles near the equator,12,13 which is three times
the median level of 37 nmol/l among adults aged ≥ 65 years in the UK in January to March.14 The enzyme
that converts 25(OH)D to its active metabolite, the steroid hormone 1,25-dihydroxyvitamin D [1,25(OH)2D]
or calcitriol, and the cognate receptor for that metabolite [the vitamin D receptor (VDR)] are expressed in
the majority of human tissues,10 not just those involved in calcium homeostasis, as was thought throughout
much of the twentieth century. Ligation of VDR by calcitriol modifies expression of > 200 genes15 to support
a wide range of biological responses that may have an impact on the pathogenesis of many diseases as well
as falls and fractures16 (Figure 1).
In keeping with these biological actions, observational epidemiological studies have reported associations
between low 25(OH)D levels and increased incidence of several cancers (particularly of the colon),
cardiovascular disease, Alzheimer’s disease and all-cause dementia, acute respiratory infection and risk of
falls and fractures.17–20 However, a recent systematic review of mortality studies21 concluded that although
all-cause mortality is consistently increased in people with 25(OH)D levels below about 75 nmol/l, several
uncertainties remain. The optimal 25(OH)D level is ill-defined owing to imperfect assay methods; for
cancers other than colon, survival after diagnosis rather than incidence may be affected; and effects on
individual cancer types and subgroups of cardiovascular disease are unclear. Last but most important,
reverse causation can be excluded only by large randomised controlled trials (RCTs). Published results of
RCTs of vitamin D supplementation conducted to date are inconclusive and may be subject to publication
bias. Some RCTs have reported protective effects for cancer incidence,22 acute respiratory infections,23–25
fractures26 and falls27 while others have not.28–34 Many of these trials suffered from one or more of the
following limitations:
l The dose of vitamin D administered was inadequate to elevate serum 25(OH)D concentration to
> 75 nmol/l.28–30
l Vitamin D deficiency was not highly prevalent at baseline.31
l There was inadequate statistical power to detect modest but clinically significant effects of
the intervention.32
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FIGURE 1 Mechanisms by which vitamin D may prevent cancer, cardiovascular disease, dementia, infections, falls and fractures. CVD, cardiovascular disease.
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The promise of a potentially safe and cost-effective intervention to reduce the incidence of several diseases
and prolong life has prompted a huge international research effort, particularly in the last decade. This has
culminated in the establishment of four very large (> 5000 participants) RCTs of higher-dose vitamin D3 in
older adults – the so-called ‘vitamin D megatrials’, defined here as RCTs of higher-dose vitamin D3 (≥ 2000 IU
per day or equivalent) in older adults with a sample size of > 5000. The primary characteristics of these
studies are summarised in PICO (Participants, Intervention, Comparator, Outcome) format in Table 1. Trials
of lower doses28,29 or of vitamin D2 rather than vitamin D335 have not been listed, as such regimens do not
produce an adequate increase in 25(OH)D.
Why then does the UK need a ‘vitamin D megatrial’ of its own?
We propose two reasons:
1. The UK represents a setting with a high prevalence of vitamin D insufficiency, where supplementation
could have maximal impact. Median serum 25(OH)D concentrations among older adults in the UK
(37–49 nmol/l, depending on season) are significantly lower than in the countries where large trials
are currently being conducted (New Zealand, 66 nmol/l;36 Australia, 69 nmol/l;37 Canada, 70 nmol/l;38
USA, 57 nmol/l39). The efficacy of vitamin D supplementation is likely to depend on the prevalence of
inadequate vitamin D status at baseline, so the results of the intervention studies conducted in these
settings are likely to underestimate any effects that would be seen in older adults living in the UK and
are less likely to achieve statistical significance. International differences in baseline vitamin D status may
be partly attributable to the fact that many of the countries listed in Table 1 are situated at lower latitudes
than the UK and, therefore, their populations have greater exposure to sunshine of sufficient intensity to
stimulate cutaneous vitamin D synthesis; moreover, many of these countries routinely fortify foods with
vitamin D (e.g. milk in the USA, Canada and Finland is routinely vitamin D-fortified).
2. Conduct of a further large trial of daily vitamin D supplementation in the UK will add substantially to
meta-analysis of these four megatrials to detect and estimate a modest but clinically significant effect
of vitamin D on all-cause mortality among participants with low serum 25(OH)D, among whom any
effect is likely to be concentrated. Apart from FIND (Finnish Vitamin D Trial)40 in Finland, which stopped
recruitment at 2500 participants (target 18,000 participants) with only 830 participants allocated to
3200 IU daily (see Table 1 footnote), the proposed trial would provide the only evidence on the effects
of a daily dose of the order of 4000 IU. Three trials (VIDA,41,42 TIPS-3 and D-Health) are testing monthly
dosing, which may be less effective. The VITamin D and OmegA-3 TriaL (VITAL), which tested 2000 IU
daily, included only 3318 participants aged ≥ 75 years,43 one-third of the number proposed in the
VIDAL main trial.
The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme did not
support our application in 2008 to conduct a large trial of vitamin D supplementation in older adults in the
UK, but invited an application for this feasibility study to establish the procedures required to conduct the
main trial. Funding was awarded in 2011 and recruitment began in 2013. An application for funding for
the main trial was made again in January 2015 when recruitment was complete, but by that time the trials
listed in Table 1 were under way and the NIHR HTA programme decided that funding for a large British
trial would not be reconsidered until the results of those trials become available. The results of the VITAL
trial, which is the only large trial of daily high-dose vitamin D, are inconclusive for all-cause mortality
[hazard ratio 2 to 5 years after entry 0.96, 95% confidence interval (CI) 0.84 to 1.11], so further evidence
is now needed.43
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TABLE 1 Characteristics of vitamin D ‘megatrials’: RCTs of higher-dose vitamin D3 (≥ 2000 IU per day or equivalent) in older adults with sample size > 5000a
Trial Setting Participants Intervention Comparator Outcome (primary) Status
VIDA New Zealand n = 5110, aged 50–84 years 100,000 IU vitamin D3 monthly p.o. Placebo Incidence of cardiovascular disease
over 5 years
Cardiovascular and bone
outcomes reported41,42
VITAL USA n = 25,875 aged ≥ 50 years
(male), ≥ 55 years (female)
2000 IU vitamin D3 daily p.o.
(2 × 2 factorial with omega-3)
Placebo Incidence of cancer and cardiovascular
disease (co-primary) over 5 years
Cardiovascular and cancer
outcomes reported43
TIPS-3 Canada, India + nine
other countries
n = 5713 aged ≥ 55 years
(male), ≥ 60 years (female)
60,000 IU vitamin D3 monthly p.o.
(2 × 2 × 2 factorial with polypill
and aspirin)
Placebo Hip fracture (primary vitamin D
outcome) over 5 years
Enrolling; due to report 2019
D-Health Australia n = 25,000 aged 60–79 years 60,000 IU vitamin D3 monthly p.o. Placebo All-cause mortality over 5 years Enrolling; due to report 2020
p.o., per os (by mouth).
a The original target for the FIND trial in Finland was 18,000, but recruitment ended in 2015 when 2500 had been randomised, with approximately 830 in each of the three arms: daily
3200 IU, 1600 IU or placebo.40
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Chapter 2 Methods
Trial design
The Vitamin D and Longevity (VIDAL) feasibility trial was a four-arm multicentre RCT of 2 years’ duration of
subjects aged 65–84 years. Twenty general practitioner (GP) practices in England were cluster randomised
in matched pairs to either double-blind or open-label study design. The GP practices were assigned to pairs
matched approximately on size, whether urban or rural, ethnic mix and ward multiple deprivation index
based on practice postcode. The practices in each pair were then randomly assigned to double-blind or
open-label individual randomisation. In double-blind practices participants were individually randomised to
blind vitamin D (BD) or blind placebo control (BC). In open-label practices individual randomisation of
participants was to open-label vitamin D (OD) or untreated open control (OC).
Ethics and regulatory approval and research governance
Ethics approval for the study was given by the London–Chelsea National Research Ethics Service in
February 2012 (reference number 11/LO/1989). Clinical trial authorisation for the study was given by
the Medicines and Healthcare products Regulatory Agency (MHRA) in March 2012 (reference number
17072/0006/001-0001). Appropriate site-specific assessments were obtained from the primary care trusts
to confer the required management permissions for the 20 participating GP practices. The trial was
registered with the International Standard Randomised Controlled Trial Register under the reference
number ISRCTN 46328341 and also with the European Union Drug Regulating Authorities Clinical Trials
(EudraCT) database under the reference number 2011-003699-34.
Patient and public involvement
Public opinion regarding the information being provided to participants of the trial was gauged in
collaboration with Barts Clinical Trials Unit (CTU). The Queen Mary Trials Advisory Group provided valuable
feedback on the patient invitation letter, information sheet and consent forms used in the trial. The lay
member and consumer representative on the VIDAL Trial Management Group also contributed from the
outset to the design of the feasibility study and provided feedback on trial management issues as they arose.
Eligibility
Members of the general population were recruited from 20 GP practices across England.
Inclusion criteria
Registered patients were considered for inclusion if they:
l were aged ≥ 65 years and ≤ 84 years at enrolment
l were contactable by telephone, able to receive recorded deliveries by post, able to attend enrolment at
the GP surgery
l had GP notes available for the previous year.
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Exclusion criteria
The study design excluded anyone:
l with known active tuberculosis, sarcoidosis, hyperparathyroidism, past or present nephrolithiasis,
vitamin D intolerance, referral for suspected hepatic or renal dysfunction, terminal illness or any
malignancy other than non-melanoma skin cancer not in remission for ≥ 3 years
l planning to move from the GP practice or to emigrate within 5 years
l with any other condition that in the principal investigator’s or chief investigator’s judgement might
compromise participant safety or compliance, interfere with evaluation or preclude completion of the study
l with a baseline corrected blood calcium level of > 2.65 mmol/l
l taking dietary supplements or other medication containing > 400 IU (10 µg) of vitamin D per day
l taking concomitant therapy with any of the following: carbamazepine, phenobarbital, phenytoin,
primidone, digoxin, oral 1-alpha-hydroxylated vitamin D preparations (e.g. alfalcalcidol, calcitriol) or the
combination of a thiazide diuretic (e.g. bendrofluazide, metolazone) with a calcium supplement
l taking treatment with any other investigational medical product or device up to 4 months before first
dose of the investigational medicinal product.
Recruitment procedure
Each of the 20 GP practices generated a list of registered patients aged 65–84 years. After excluding
ineligible individuals, including those judged by the GP to lack the mental capacity to give informed
consent or to be unsuitable for other reasons, study invitations were sent by post to potential participants.
Interested respondents were telephoned by a member of the research team at the GP practice to confirm
eligibility and arrange a baseline assessment appointment at the GP practice, at which time informed
consent was obtained from those agreeing to participate in the trial. Trial participants then provided
information on current medications and conditions, diet (including dietary supplements), skin type and sun
exposure, and QoL (see Appendix 1). Virtually all information was entered directly into case report forms
(CRFs) accessed via the online clinical data management system [the VIDAL app (online application);
see Appendix 2], with paper copies of all CRFs available as a back-up option. Systolic and diastolic blood
pressure (BP), height, weight and waist circumference were recorded, and 12.5 ml of blood [9 ml ethylene
diamine tetra-acetic acid (EDTA) vacutainer for measurement of 25(OH)D and 3.5 ml serum separator
tube (SST) vacutainer for calcium assay] were obtained. The 3.5-ml aliquot was sent for corrected calcium
assay at the practice’s local laboratory to verify eligibility. The 9-ml aliquot was sent to the Clinical Trials
Service Unit in Oxford for separation of buffy coat and storage in liquid nitrogen. Circulating 25(OH)D
was assayed on all stored samples (baseline and 2-year follow-up) at the end of the study on the Cobas
6000 immunoassay (Roche Molecular Diagnostics, Pleasanton, CA, USA).
Informed consent
Informed written consent was obtained during the baseline assessment from eligible participants after an
explanation of the aims, methods, anticipated benefits and potential hazards of the study. The original
signed and dated consent forms were held at each GP practice, with copies sent to the participant and
the Trial Coordination Centre. Patients ineligible for inclusion, based on the corrected blood calcium
result, were informed of this by their GP or GP nurse, who also discussed whether or not any treatment
was indicated.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Randomisation, concealment and blinding
Cluster randomisation of GP practices
Prior to study commencement, 20 GP practices were matched as closely as possible in pairs based on
urban/rural location, deprivation [Index of Multiple Deprivation (IMD) of the ward of the GP practice based
on the GP practice postcode], practice size and ethnic mix (non-white proportion). Practices were then
randomised within each pair, one to the double-blind study and one to the open-label study, by the
Biostatistician and Director of the Barts CTU, a UK Clinical Research Collaboration registered Trials Unit.
Four GP practices (including both in one pair) withdrew after randomisation, so these were replaced and
the three pairs were re-randomised.
Individual randomisation of eligible participants within the practices
Individual participants were subsequently randomised within GP practices using the VIDAL app developed
by the Barts CTU. The VIDAL app generated a random sequence of allocations for each GP practice
balanced in blocks of six or eight so that the next participant’s allocation could not be predicted. Allocation
of treatment was concealed from all participants, GP practices and researchers in the blind arm of the trial.
Only the independent senior programmer at Barts CTU, who wrote the randomisation code on the VIDAL
app, had access to this code.
On receipt of an eligible corrected blood calcium result and after verifying participant eligibility and consent,
the Trial Coordination Centre telephoned potential participants to confirm their willingness to be randomised.
Randomisation was then performed by the automated system on the VIDAL app.
Participants randomised to a treatment arm (BD, BC or OD) were then sent a 1-year supply of study
medication by recorded delivery from the dispensing pharmacy. The second year’s study medication was
allocated automatically by the VIDAL app 1 year later and sent by the same procedure. Participants allocated
to OC at randomisation received a letter from the Trial Coordinating Centre explaining that they would be
recontacted at 2 years for a follow-up visit and a further blood sample.
The study participants who were enrolled at the blind practices received annual study medication packs,
each containing 12 monthly doses of study oil labelled as ‘vitamin D3 oil/placebo oil’. Each pack contained
12 bottles containing either 5.2 ml cholecalciferol (Vigantol® Oil; Merck Serono GmbH, Germany) – an oily
solution of vitamin D3, concentration 0.5 mg/ml – or 5.2 ml placebo, a pharmacopoeia-listed mixture of palm
oil and coconut oil containing medium-chain triglycerides (Miglyol® 812; Caesar & Loretz GmbH, Germany).
Study participants enrolled at open-label practices who were allocated to vitamin D (OD arm) received
annual study medication packs each containing 12 monthly doses of study oil labelled as ‘vitamin D3 oil’.
Each of the 12 bottles contained 5.2 ml, cholecalciferol.
The bottles of medication contained 5.2 ml to ensure delivery of 5 ml (2.5 mg of vitamin D3) because ≈ 0.2 ml
of the oily solution adheres to the sides of the bottle.
Follow-up
To obtain information on their vitamin D consumption for an interim report, 121 participants who were
randomised to the no treatment arm in open practices (OC arm) before May 2014 were contacted by post,
e-mail or telephone in December 2014. There was no other contact after randomisation with the OC
participants until they were invited to attend the 2-year final visit. All other study participants (i.e. those
allocated to active treatment or placebo) were contacted at least once per month post randomisation by
their preferred medium, as described in the following paragraphs. Letters were sent by CFH Docmail Ltd
(Radstock, UK) on behalf of the participating GP practices, with responses sent directly back to the study
participant’s GP practice.
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Automated telephone call, e-mail or text message every month from month 1 to month 24
All participants except those randomised to OC (no treatment) were reminded to take their study medication
every month by automated telephone call, e-mail or text message generated by the VIDAL app.
E-mail or letter follow-up at months 3, 6, 9, 12, 15, 18, 21 and 24
All participants except those who were randomised to the OC (no treatment) arm were contacted quarterly
either by post from their GP practice or by e-mail from the VIDAL app (depending on the participant’s
choice of medium). The participants were asked to send a short reply by the same medium. E-mails to the
VIDAL app were recorded automatically. The reply recorded the dates on which the last three doses of
study medication were taken or reasons for non-compliance, any planned change of address and any
hospital admissions. The 3-monthly follow-up also included a reminder for participants to contact their
GP if they were experiencing ongoing symptoms of hypercalcaemia (persistent nausea, vomiting, thirst,
passing excessive amounts of urine or feeling generally unwell).
The Trial Coordinating Centre also monitored serious adverse events (SAEs), adverse reactions (ARs) and
compliance during follow-up.
General practitioner practice visit at month 24
Two years after randomisation, all participants were invited to attend their GP practice for the 2-year visit
to obtain a repeat blood sample for 25(OH)D assay, a BP measurement and responses to the same lifestyle
questions as at baseline. Current consumption of any medication or supplement containing vitamin D was
recorded to assess contamination.
Each GP practice also examined all treatment packs brought in at the 2-year visit, cross-checking unused
study oil bottles and the study oil dose dates recorded by each participant on the exterior of the treatment
pack against the compliance information supplied in the quarterly follow-up form.
Summaries of GP records for all randomised participants were extracted by the practice staff to obtain
prospectively recorded information about GP visits, prescriptions and infections over the preceding 3 years
(1 year pre randomisation and 2 years during the trial).
Automated follow-up
Cause-specific mortality, cancer incidence and hospital records were obtained by linking NHS number,
date of birth and postcode to medical records held by NHS Digital on cancer registrations (provided by
NHS Digital on behalf of Public Health England), deaths (from civil registration data and provided by NHS
Digital on behalf of the Office for National Statistics) and the Hospital Episode Statistics (HES) database
(from March 2012 to March 2017) on hospital admissions.44
Interim Data Monitoring Committee reports
A Data Monitoring Committee (DMC) was convened. Interim safety analyses were conducted twice during
the feasibility study. The independent statistician conducted an analysis to compare the incidence of SAEs
between intervention and control arms for review by the DMC. Had there been a significant difference
(p < 0.05) in the incidence of fatal or life-threatening adverse events, the DMC would have been informed
and would have discussed whether or not the sponsor and ethics committee should be consulted regarding
stopping the trial, but this did not arise.
METHODS
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Trial outcomes
Primary outcomes
The primary aim of the feasibility study was to establish the procedures required to conduct the main trial
and to determine the time taken to recruit and randomise 1600 participants aged 65–84 years. The aims
of the cluster randomisation of practices were to:
i. compare response (number randomised/number invited) and attrition (attendance at 2-year final visit) in
blind and open practices
ii. compare allocated treatment compliance among open-label (OD) participants and blind (BC or BD)
participants
iii. compare contamination rates (the proportion taking > 400 IU per day of vitamin D), particularly
between open untreated control (OC) and blind (BC or BD) participants.
Secondary outcomes
i. Comparison of reported SAEs between vitamin D and control participants in blind practices provides a
conventional safety measure. OC participants did not receive quarterly follow-ups and therefore did not
report SAEs, which were recorded only retrospectively at the 2-year follow-up.
ii. Comparison of numbers of infections and GP visits between vitamin D and control participants (a) in
blinded practices, and (b) in open-label practices. This provides an estimate of the bias in these measures
with open-label randomisation.
iii. Blood 25(OH)D concentration at recruitment and at 2 years in relation to allocated treatment and other
potential determinants of vitamin D status including self-reported sun exposure, latitude, consumption
of oily fish and use of vitamin D supplements.
iv. Comparison of change in systolic and diastolic BP from recruitment to 2 years between the vitamin D
arm and the control arm.
Sample size
The aim of the feasibility study was to recruit 1600 participants aged 65–84 years through 20 GP practices
[400 on OD vs. 400 on OC; 400 in the blind vitamin D (BD) arm vs. 400 in the blind placebo control (BC)
arm]. The target was to randomise an average of 80 participants aged 65–84 years per GP practice with at
least 9% response (number randomised/number invited). If recruitment in some GP practices fell below this
target, recruitment in other practices would be continued after 80 participants had been randomised to
achieve the overall target of 1600 participants.
Power
The main purpose of the feasibility study was to pilot the organisational procedures for the main trial,
to demonstrate adequate recruitment and compliance and to prepare for any unexpected difficulties in
running the trial. The number of practices involved was considered large enough to be representative of
the diversity of practices that may participate in the main trial, so that average participation (the proportion
of those invited who are randomised) could be considered a reliable estimate of what would be achieved
in the main trial.
The proposed feasibility study also had adequate power to detect a 5% difference in participation between
open-label and blind practices with a nominal two-sided alpha level of 5%, comparing blind and open
designs in 10 pairs of practices, with each practice recruiting 80 participants. To estimate the power, we
simulated the number of registered GP practice patients who one would need to approach in each practice
to recruit 80 participants (negative binomial). The cluster randomisation was powered to detect a change
in the mean participation rate from 10% (range 2.5% to 17.5%) to 15% (5.7% to 24.3%). Under these
assumptions the probability of detecting this difference at p < 0.05 would be 92%. (If there were no
heterogeneity between practices the overall recruitment rate would be estimated more precisely, e.g. 9%
with standard error 0.2%.)
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In addition, to detect a difference of 10% in any binary outcome, the trial had (at least) 80% power (using
a nominal 5% significance level) for any overall comparison, such as vitamin D versus placebo (400 per
arm), and 70% power for any between-practice comparison, such as BC versus OC (sign test with 10 pairs
of practices; power = 70% for 0.45 vs. 0.55, and 88% for 0.10 vs. 0.20). The outcome might be reporting
a respiratory infection (15% vs. 25%) or compliance (85% vs. 95%). The pre-specified definition of
‘composite compliance’ was that a randomised participant should attend the 2-year visit, and:
i. if allocated to vitamin D, report taking at least 19 (79%) of the 24 monthly doses of the allocated
investigational medicinal product, or
ii. if allocated to no vitamin D (BC or OC), report taking a total of < 300,000 IU of vitamin D supplements
over the 2 years of the study. (The current UK reference nutrient intake of 400 IU per day is 292,000 IU
over 2 years.)
Statistical methods
All analyses were performed on an intention-to-treat basis using Stata® version 15 (StataCorp LP, College
Station, TX, USA). Wilcoxon’s signed-rank test was used for comparisons of blind versus open practices
within matched pairs.
Response rates
The GP practices were able to provide anonymised data on the number of participants they approached
to take part in the trial by 5-year age group and by sex. No further variables were available. From these
totals, participation rates were calculated. Estimated numbers of replies are shown for two practices
(1O and 3B) that did not record the number of reply slips, and for one (9B) that invited all 960 eligible
patients, received 170 replies and stopped recruitment when 100 had attended the baseline visit. The
numbers of replies at these three practices were estimated by assuming the same ratio of replies to
baseline visits as at other practices with the same allocation (open or blind). The number of invitations
required by practice 9B to give the estimated 108 replies was estimated as 960 × (108/170).
Compliance
Data from quarterly follow-ups and the 2-year visit were used to calculate the overall number of study
medication doses taken. The percentage of participants taking all three doses was calculated in each
quarter and tabulated by GP practice and treatment allocation. The proportion of participants taking at
least one dose was also calculated in each quarter. Participants were defined as having stopped taking
medication at the 2-year follow-up if they took fewer than two doses in the last quarter of the trial. The
reasons for stopping study medication, as given on the withdrawal form, were tabulated by allocated
treatment and study arm.
Contamination
The daily dose of any supplements containing vitamin D was self-reported at baseline and at the follow-up
visit. Participants reporting taking cod liver oil were assumed to be consuming 200 IU per day of vitamin D.
Details of prescriptions were also downloaded from GP records, but some did not record frequency,
so daily dose could not always be calculated accurately. Doses of medication indicated from prescription
data that could not be verified from self-reported medication data were assumed to be 800 IU per day.
Self-reported and prescription data have been tabulated separately.
Summary measure of compliance
The single measure of ‘composite compliance’, defined above, was pre-specified to avoid multiple testing
in the power calculation. This was calculated as described using the compliance and contamination data.
Participants who died during the 2-year trial period were excluded from this analysis. The definition required
control participants not to exceed 300,000 IU over the 2 years of the trial; however, a conservative approach
METHODS
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was taken such that any control participants who reported taking, or were prescribed, supplements exceeding
400 IU per day at either baseline or follow-up were considered non-compliant.
Deprivation
English indices of multiple deprivation (IMD) for 2015 were downloaded for each participant’s home
postcode.45 These produce the IMD by small areas of approximately 650 households. We also used the
Income Deprivation Affecting Older People Index (IDAOPI), grouping deciles of IDAOPI into quintiles.
Blood 25(OH)D
Mean blood 25(OH)D levels at baseline were categorised on demographic and lifestyle factors. Multivariate
linear regression was used to calculate the adjusted means of 25(OH)D and trend p-values across categories
for each factor (see Table 14). The adjusted means are the estimated marginal means, which are standardised
to the observed distribution on all other variables. The suboptimal threshold was defined as blood 25(OH)D
< 75 nmol/l.
Linear regression was used to assess change in blood 25(OH)D from baseline to the 2-year visit with
respect to allocated treatment. As a secondary analysis, the change in season was also adjusted for,
only slightly modifying the estimates. Vitamin D levels were lower in winter and spring and therefore a
variable was constructed to represent change in season: summer/autumn to winter/spring, same season,
winter/spring to summer/autumn.
Infections and GP visits
Data downloaded from GP notes were used to identify visits to the GP when an infection was diagnosed.
Infections were categorised into five categories: upper respiratory, lower respiratory, urinary, skin/mucosal
or soft tissue, and other. Multiple visits were combined by ignoring subsequent visits within the same
category within 2 weeks. Infections were tabulated by allocated treatment and baseline blood 25(OH)D.
Numbers of infections and visits were calculated in the year preceding the randomisation date and in the
2 years of the trial.
Cancer, mortality and hospital admissions data
Cancer incidence data were available until April 2017, just over 2 years after the last patient was
randomised. The numbers of incident cancer diagnoses within 2 years of randomisation were tabulated;
skin cancers and benign and in situ tumours were excluded. HES data44 were complete until March 2017,
providing complete data on emergency hospital admissions within 2 years of randomisation for all patients.
Numbers of admissions by treatment arm were also available for the year preceding randomisation.
Mortality data were available until February 2018, 3 years after the last patient was randomised.
Other measurements
Quality of life was measured at baseline and 2 years after randomisation using the standardised EuroQol-5
Dimensions, three-level version (EQ-5D-3L), health status instrument46 consisting of two elements: (1) a
simple descriptive profile comprising five dimensions (i.e. mobility, self-care, usual activities, pain/discomfort
and anxiety/depression) and (2) the EQ analogue scale, a single index value for health status. The descriptive
dimensions each comprised three levels: no problems, some problems and extreme problems. These levels
were assigned a score of 1, 2 and 3 respectively and a total score calculated from adding all five values,
where a score of 5 equated to best possible health and a score of 15 equated to worst possible health.
For the tables, these were categorised into five groups equating to a score of 5, 6, 7, 8 or ≥ 9. The EQ visual
analogue scale records each respondent’s self-rated health that day as a score between 1 and 100, where 1
is the worst imaginable health state and 100 is the best imaginable health state. This was adapted by asking
participants to give a number between 1 and 100 instead of marking their score on a scale (see Appendix 1).
Changes in BP, height, weight, body mass index (BMI) and self-reported health score (given as a percentage)
were calculated. Univariate linear regression models for each of these were fitted to estimated mean changes
by allocated treatment.
DOI: 10.3310/hta24100 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 10
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Rake et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11

Chapter 3 Results
Recruitment
The CONSORT (Consolidated Standards of Reporting Trials) flow diagram summarising the number of
individuals participating at each stage of the trial is shown in Figure 2. In addition to data collected from
the participants at study visits, data regarding prescriptions, infections and GP visits were downloaded from
each GP database. GP data were obtained for 1554 participants (96.2%) but this varied by GP practice.
Open randomisation to vitamin D vs. no treatment
(n = 828)
OC
(n = 421)
OD
(n = 407)
Lost to
follow-up
(n = 90)
Lost to
follow-up
(n = 66)
• Died, n = 4
• Other, n = 51
• Died, n = 8
• Other, n = 27
Attended final follow-up
(n = 738)
Attended final follow-up
(n = 721)
n = 366 (86.9%) n = 372 (91.4%)
BC
(n = 392)
BD
(n = 395)
n = 366 (93.4%)
Double-blind randomisation to vitamin D vs. placebo
(n = 787)
n = 355 (89.9%)
• Died, n = 3
• Other, n = 23
• Died, n = 5
• Other, n = 35
Postal invitation
(n = 5508)
Postal invitation
(n = 5868)
Double-blind arm
(n = 10 GP practices)
Cluster randomisation of 20 GP practices
Open arm
(n = 10 GP practices)
• Declined invitation or
   no reply slip, n = 4513
• Other, n = 138
• Declined invitation or
   no reply slip, n = 4985
• Other, n = 67
Baseline visit
(n = 857)
Baseline visit
(n = 816)
• Declined randomisation,
   n = 2
• Hypercalcaemic, n = 3
• Other, n = 24
• Declined randomisation,
   n = 5
• Hypercalcaemic, n = 8
• Other, n = 16
FIGURE 2 The VIDAL trial CONSORT flow diagram.
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Some practices did not provide data from patients who had moved GP or who had died, as these data
were no longer available on their computer systems. Figure 3 shows cumulative recruitment. The pilot
practice began recruiting in April 2013. Main recruitment began in October 2013 and ended in January
2015 with 1615 participants randomised (the target was 1600 participants). The recruitment period for
individual practices ranged from 4 to 12 months.
Table 2 shows the numbers of registered patients in each practice invited, replying, attending the baseline
visit and randomised. GP practice codes indicate matched pair (0–9) and whether or not randomisation
was open-label or blind (O or B).
The overall recruitment rate (number randomised/number invited) was 14.2%. The rate was higher in open
(15.0%, range 8.8–22.4%) than in blind practices (13.4%, range 8.8–26.4%), but this did not approach
statistical significance because of the wide variation between practices (Wilcoxon signed-rank test; p = 0.7).
Table 3 shows that the recruitment rate was lower (p = 0.002) in participants aged 80–84 years (11.5%)
than in participants aged < 80 years (14.6%), and was lower in women than in men (p = 0.002).
Table 4 shows the 1615 randomised participants by age and sex. There were 857 (53.1%) men and 758
(46.9%) women, with similar age distributions. The majority (70.2%) were aged 65–74 years and only
9.7% were 80–84 years. Almost all were white (Table 5: 1600/1615). Table 6 shows numbers by age and
sex of those who chose to receive and return quarterly follow-ups by e-mail. The proportion choosing
e-mail was higher among men and declined with age, from 77.4% in those aged 65–69 years to 36.5%
in those aged 80–84 years. The proportion choosing e-mail for monthly reminders to take their study
medication also declined with age, from 70.5% (440/624) of those aged 65–69 years to 33.3% (52/156)
of those aged 80–84 years, most of whom (79.5%) requested a monthly telephone call. The proportion
requesting text message reminders declined from 40.1% (250/624) in those aged 65–69 years to 9.0%
(14/156) in those aged 80–84 years (more than one medium could be chosen).
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FIGURE 3 Cumulative VIDAL recruitment by month and year.
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TABLE 2 Participation rates and numbers randomised by GP practice (estimated numbers in brackets). GP practice
codes indicate matched pair (0–9) and allocated to open-label or blind individual randomisation (O or B)
GP practice
Number
invited
Reply slips
received
Attended
baseline visit
Number
randomised % randomised OC OD BC BD
0B (pilot) 690 83 81 72 10.4 36 36
0O 348 95 80 78 22.4 42 36
1B 659 81 80 79 12.0 39 40
1O 500 (97) 84 83 16.6 47 36
2B 680 60 63 60 8.8 30 30
2O 316 77 67 60 19.0 28 32
3B 476 (88) 81 73 15.3 35 38
3O 450 112 86 83 18.4 44 39
4B 528 74 65 65 12.3 34 31
4O 616 64 57 54 8.8 28 26
5B 375 129 102 99 26.4 48 51
5O 450 91 86 81 18.0 36 45
6B 500 95 82 80 16.0 39 41
6O 705 78 78 76 10.8 38 38
7B 1000 81 78 77 7.7 39 38
7O 805 176 159 156 19.4 79 77
8B 350 84 84 84 24.0 43 41
8O 479 90 80 78 16.3 36 42
9B (610) (108) 100 98 (15.5) 49 49
9O 839 115 80 79 9.4 43 36
Total 11,376 1878 1673 1615 14.2 421 407 392 395
TABLE 3 Participation rates and numbers randomised by age group and sex
Participants Number invited Number randomised % randomised
Age group (years)
65–69 4599 624 13.6
70–74 3122 510 16.3
75–79 2297 325 14.2
80–84 1358 156 11.5
Sex
Male 5631 857 15.2
Female 5745 758 13.2
Total 11,376 1615 14.2
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Compliance
Tables 7 and 8 and Figure 4 show compliance among the 1194 participants randomised to receive study
medication (the blind treatment arms or the OD arm). Excluding participants who died during the trial
period, 89.9% (1059/1178) were still taking medication at the end of the study, 91.2% in the OD arm and
89.2% in the blind treatment arms. All 24 doses of study medication were taken by 80.2% (625/779) of
participants in the blind treatment arms and 83.2% (332/399) of those in the OD arm. Eleven participants in
the blind treatment arms (1.5%) and four (1.0%) in the OD arm did not take any study medication from the
outset. Compliance was higher among men than among women and among participants aged < 75 years:
all 24 doses were taken by 86.6% of men and 79.0% of women aged < 75 years, and by 83.8% of men
and 69.9% of women aged ≥ 75 years.
TABLE 4 Randomised individuals by age and sex
Age group (years) Male, n (%) Female, n (%) All randomised, n (%)
65–69 341 (39.8) 283 (37.3) 624 (38.6)
70–74 253 (29.5) 257 (33.9) 510 (31.6)
75–79 177 (20.7) 148 (19.5) 325 (20.1)
80–84 86 (10.0) 70 (9.2) 156 (9.7)
Total 857 (100) 758 (100) 1615 (100)
TABLE 5 Randomised individuals by ethnicity
Ethnicity n (%)
White British 1563 (96.8)
White Irish 11 (0.7)
White other 26 (1.6)
Caribbean 6 (0.4)
Asian 6 (0.4)
Mixed 3 (0.2)
Total 1615 (100)
TABLE 6 Proportion of those randomised choosing e-mail, text message or automated telephone call for their quarterly
follow-ups and monthly reminders, by age group and sex (more than one could be chosen for monthly reminders)
Method
Males (years) Females (years)
65–69 70–74 75–79 80–84 65–69 70–74 75–79 80–84
Quarterly follow-up, n (%)
E-mail 274 (80.4) 182 (71.9) 114 (64.4) 37 (43.0) 209 (73.9) 163 (63.4) 67 (45.3) 20 (28.6)
Monthly reminder, n (%)
E-mail 249 (73.0) 158 (62.5) 105 (59.3) 34 (39.5) 191 (67.5) 142 (55.3) 60 (40.5) 18 (25.7)
Text 135 (39.6) 84 (33.2) 38 (21.5) 10 (11.6) 115 (40.6) 85 (33.1) 27 (18.2) 4 (5.7)
Telephone 140 (41.1) 123 (48.6) 105 (59.3) 66 (76.7) 118 (41.7) 148 (57.6) 108 (73.0) 58 (82.9)
Total 341 253 177 86 283 257 148 70
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TABLE 7 Compliance of participants per quarter (percentage of those randomised taking all three monthly doses) by GP practice among 1194 patients taking study medication
and number of participants attending the 2-year visit (of the 1595 still alive at the end of the trial)
Practice Total randomised Randomised to treatment
Compliance (% of randomised participants taking all three doses)
Attended the
2-year visita
3 month 6 month 9 month 12 month 15 month 18 month 21 month 24 month n (%)
0B 72 72 95.8 93.1 88.9 90.3 88.9 86.1 84.7 80.6 64 (88.9)
0O 78 36 97.2 97.2 97.2 97.2 97.2 97.2 97.2 97.2 70 (89.7)
1B 79 79 96.2 96.2 94.9 93.7 92.4 89.9 88.6 89.9 74 (93.7)
1O 83 36 100.0 100.0 100.0 94.4 94.4 94.4 94.4 88.9 76 (91.6)
2B 60 60 100.0 98.3 98.3 98.3 98.3 95.0 91.7 90.0 54 (91.5)
2O 60 32 96.9 90.6 90.6 90.6 90.6 87.5 87.5 87.5 53 (88.3)
3B 73 73 98.6 98.6 91.8 90.4 89.0 89.0 89.0 87.7 64 (88.9)
3O 83 39 100.0 100.0 100.0 100.0 100.0 100.0 100.0 97.4 73 (89.0)
4B 65 65 96.9 93.8 89.2 83.1 81.5 81.5 81.5 80.0 52 (83.9)
4O 54 26 96.2 92.3 88.5 88.5 88.5 84.6 84.6 80.8 42 (79.2)
5B 99 99 100.0 99.0 98.0 97.0 94.9 93.9 93.9 93.9 96 (97.0)
5O 81 45 95.6 95.6 95.6 93.3 93.3 93.3 93.3 93.3 75 (93.8)
6B 80 80 98.8 95.0 95.0 92.5 92.5 91.3 90.0 88.8 73 (91.3)
6O 76 38 100.0 97.4 94.7 92.1 92.1 92.1 92.1 89.5 70 (93.3)
7B 77 77 98.7 98.7 98.7 97.4 97.4 97.4 96.1 96.1 75 (98.7)
7O 156 77 97.4 97.4 96.1 96.1 92.2 92.2 89.6 88.3 142 (92.2)
8B 84 84 97.6 94.0 94.0 90.5 84.5 84.5 83.3 82.1 75 (90.4)
8O 78 42 95.2 85.7 83.3 83.3 81.0 76.2 76.2 76.2 60 (82.2)
9B 98 98 99.0 96.9 96.9 95.9 95.9 94.9 93.9 90.8 94 (96.9)
9O 79 36 100.0 100.0 100.0 97.2 97.2 97.2 94.4 94.4 77 (98.7)
Total 1615 1194 98.1 96.2 94.8 93.3 92.0 91.0 90.0 88.7 1459 (91.5)
a Twenty deceased participants are excluded from the denominator.
D
O
I:10.3310/hta24100
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2020
VO
L.24
N
O
.10
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2020.This
w
ork
w
as
produced
by
Rake
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
17
Occasional doses were missed for various reasons and so a more useful measure of compliance is the date
when a participant last took their study medication. Within 6 months of entry, 16 (4.0%) participants allocated
to OD and 34 (4.4%) on blind treatment (BC or BD) had stopped taking study medication. The subsequent rate
of decline (Figure 5), which was slightly lower, is likely to provide a better estimate of the proportion who would
continue treatment in a longer trial. Among those compliant at 6 months, 6.2% (70/1128) stopped taking
medication over the remaining 18 months of the trial [5.0% (19/383) on OD and 6.8% (51/745) on blind
treatment; p = 0.21], which is an overall annual attrition of 4.1% per year. If this rate of attrition continued,
81.1% of all randomised participants would still be taking allocated medication at the end of a 5-year trial.
Treatment compliance and withdrawal
For mortality (the primary end point in the main trial for which this is the feasibility study), there were no
withdrawals from follow-up, because all participants will continue to be followed up through NHS Digital
unless they are censored at emigration. Table 9 shows the reasons given by 13 (3.1%) of 421 OC participants
who notified the practice that they wished to withdraw from the trial, either because they began taking
> 400 IU per day of vitamin D or because they would not attend the 2-year follow-up (this includes two
participants who started taking vitamin D during the trial but returned for the 2-year follow-up). Table 9 also
shows reasons for stopping treatment for 137 (11.5%) of 1194 participants allocated to treatment who stopped
taking medication before the 2-year visit, including 16 participants who died and 45 participants who attended
the 2-year visit. In the blind practices, 11.0% of participants stopped taking study medication compared
with 8.8% of those allocated to vitamin D in open practices (Wilcoxon signed-rank test; p-value = 0.4). The
proportion of participants who stopped their medication increased with the number of days spent in hospital
over the 2-year trial period according to HES data:44 8.5% of those without hospital admissions, 27% (30/109)
of those spending < 10 days in hospital and 53% (16/30) of those spending > 10 days in hospital.
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FIGURE 4 Compliance of participants taking study medication in each quarter (percentage of those randomised
taking all three monthly doses vs. at least one dose) by randomisation method (blind or open-label).
TABLE 8 Compliance of participants allocated to study medication: number of doses taken by study arm. Those
randomised to receive no treatment in open practices are excluded
Total number of doses taken Blind treatment arms, n (%) OD, n (%) Total, n (%)
0–5 28 (3.6) 18 (4.4) 46 (3.9)
6–11 31 (3.9) 9 (2.2) 40 (3.4)
12–17 21 (2.7) 8 (2.0) 29 (2.4)
≥ 18 707 (89.8) 372 (91.4) 1079 (90.4)
Total 787 407 1194
RESULTS
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Table 10 shows that 91.5% (1459/1595) of all surviving randomised participants returned for the 2-year
visit. A viable blood 25(OH)D result was obtained for 1456 of them. As expected, a higher proportion
of surviving participants in the three study medication arms than in the OC arm attended the 2-year visit
(93.2% OD vs. 87.8% OC in open practices; p = 0.008) (92.6% BD and BC in blind practices). The proportion
returning for the 2-year visit decreased with increasing number of days in hospital according to HES data:44
92.6% (1318/1424) of those without stays in hospital attended the follow-up visit compared with 79.9%
(119/149) of those spending < 10 days in hospital and 52.4% (22/42) of those spending ≥ 10 days in hospital
within the 2-year trial period.
TABLE 9 Reasons for 13 notified withdrawals in OC arm and reasons for stopping medication in treated
participants as reported by participants
Variable
Open practices Blind practices
OC OD BC BD All blind patients
Reason for withdrawal
AR to oil NA 11 7 7 14
Illness 3 8 4 12 16
Moved out of the area 4 4 6 6 12
Other reason 3 8 10 8 18
Decided to take vitamin D 2 0 1 1 2
Prescribed vitamin D 1 3 9 5 14
No reason given 0 1 1 8 9
Total stopping medication excluding
deaths, n (%)
35 (8.8) 38 (9.8) 48 (12.3) 86 (11.0)
Deceased 4 8 3 5 8
Totals
Randomised participants 421 407 392 395 787
Continued taking medication NA 364 351 342 693
AR, adverse reaction; NA, not applicable.
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FIGURE 5 Proportion of participants who were compliant at 6 months still taking study medication over the
remainder of the trial. Within 6 months of entry 4.0% of participants allocated to OD and 4.4% on blind treatment
had stopped taking study medication.
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Contamination
Table 11 shows that almost one-quarter of participants (23.2%) reported taking self-administered daily
supplements containing vitamin D at baseline, but the majority of these contained ≤ 200 IU (5 µg). GP notes
abstracted at the end of the study revealed that an additional 17 (1.1%) participants were being prescribed
medication containing vitamin D at baseline, including six at > 400 IU per day. These six, together with the
three individuals who were taking > 400 IU (10 µg) per day (see Table 11 footnote a), were missed by the
practice nurse when eligibility was checked at baseline. At follow-up, the proportion reporting self-administered
supplements containing vitamin D (16.5% overall) had fallen in the OD arm and in both blind treatment arms
but remained unchanged in the OC arm. The proportion of individuals taking high-dose vitamin D increased
in the OC arm and the blind treatment arm, but only four individuals reported taking > 1000 IU (25 µg) per
day. At 2 years, 3.6% of participants with available data were receiving > 400 IU per day of additional
vitamin D (1.1% self-administered, 2.2% prescribed). Contamination data were collected by telephone from
65 participants who did not attend the 2-year visit but remained unknown for 91 participants, including 20
who died during the trial and a further three who died before the telephone follow-up call.
Composite compliance
‘Composite compliance’, as defined in Chapter 2, Methods, was calculated for all participants who did
not die within 2 years of randomisation. All between-practice differences were tested using Wilcoxon‘s
signed-rank test with 10 matched pairs of practices. Among the control participants, a significantly higher
proportion were compliant in blind practices than in open practices (89.7% BC vs. 83.0% OC; p = 0.01).
This difference was a result of the lower attendance among untreated OCs at the follow-up visit (94.1% BC
vs. 87.8% OC; p = 0.01), as the proportions exceeding the permitted total dose of vitamin D supplements
(300,000 IU over 2 years) were similar. There was an opposite but non-significant difference for the
composite compliance variable among those allocated to vitamin D, with higher compliance among open
practices (91.0% OD vs. 86.9% BD; p = 0.07) owing to slightly higher attendance at the follow-up visit
(93.2% OD vs. 91.0% BD) and a slightly higher proportion taking at least 19 doses (92.7% OD vs. 89.2% BD).
These opposite effects led to similar overall composite compliance of 88.3% (688/779) in the blind practices
and 86.9% (709/816) in the open practices (p = 0.43).
Safety
At least one SAE was reported during the 2-year trial period for 11.6% of participants allocated to study
medication (Table 12), the majority of which resulted in hospitalisation. None of the 184 reported SAEs
was judged to be associated with the study medication. There were no significant differences between the
SAEs reported between the vitamin D arms and the blind placebo arm. Only seven SAEs were not a cancer
diagnosis, did not necessitate hospitalisation and did not result in death. The SAEs were not reported during
the trial by patients in the untreated OC arm of the study, as they did not return quarterly follow-up forms.
TABLE 10 Number of randomised participants returning for 2-year visit by treatment arm
GP practice visit
Open practices
Blind practices TotalOC OD
Baseline 421 407 787 1615
2-year visit 366 372 721 1459
% returning for 2-year visita 87.8 93.2 92.6 91.5
Deceased 4 8 8 20
a Deceased participants are excluded from the denominator.
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TABLE 11 Contamination: additional self-administered or GP prescribed daily vitamin D from all supplements being
taken at baseline and at the 2-year visit (combined data from self-report and GP records)
Daily vitamin D in addition
to study medication
Open practices Blind practices
TotalOC OD BC BD All blind
Baseline visit
None 327 305 297 295 592 1224
Self-administered
≤ 200 IU 75 76 73 78 151 302
201–400 IU 15 23 14 17 31 69
401–1000 IU 1a 0 2 0 2a 3
GP prescribed
≤ 400 IU 1 3 4 3 7 11
> 400 IU 1 2 2 4 5
Dose NKb 1 1
% > 400 IU 0.7 0.0 1.0 0.5 0.8 0.6
2-year visit
None 304 318 304 297 601 1223
Self-administered
≤ 200 IU 54 46 36 47 83 183
201–400 IU 18 10 9 10 19 47
401–1000 IU 8 2 4 3 7 17
> 1000 IU 1 1c 2 0 2d 4
GP prescribed
≤ 400 IU 4 2 6 4 10 16
> 400 IU 10 2 6 3 9 21
Dose NKb 1 3 6 3 9 13
% > 400 IU among responders 5.0 2.1 4.8 2.5 3.6 3.6
Totals at 2-year visit
Attended 2-year visit 366 372 366 355 721 1459
Telephoned at 2 years 34 12 7 12 19 65
No data 17 15 16 23 37 71
Deceased 4 8 3 5 8 20
All randomised participants 421 407 392 395 787 1615
NK, not known.
a These three participants were taking 400 IU of vitamin D per day. Two were also taking cod liver oil and one was taking
a multivitamin supplement containing 400 IU of vitamin D. These additional supplements were missed by the practice
staff when checking eligibility at the baseline visit. (The protocol specified a daily maximum of 400 IU in addition to
study treatment.)
b Assumed to be > 400 IU per day.
c This participant randomised to take OD stopped taking study medication after 2 months because of an AR to the oil and
began taking vitamin D (1200 IU per day).
d Two participants in the BC arm stopped taking study medication after 8 months. One had been prescribed vitamin D
(5000 IU) by their GP and one believed they were on placebo and started taking vitamin D (2500 IU).
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Rates of emergency hospitalisation from HES data44 are slightly higher than the self-reported episodes for
the patients allocated to study medication (11.6% vs. 10.4%), and much higher for OCs (12.4% vs. 1.7%),
as expected. There were no significant differences in the hospitalisation rate between the open and blind
arms of the trial (11.8% in both arms spent at least one night in hospital). Very few participants were
hospitalised for > 30 days in total during the 2 years following randomisation [8/813 (1.0%) in the control
arms and 7/802 (0.9%) in the vitamin D arms]. Table 12 shows that the notification source for 116 (91.3%)
of the 127 patients with SAEs other than death was self-report on quarterly follow-up forms (n = 101) or
retrospective report at the 2-year follow-up (n = 15). GPs reported only an additional 11 non-fatal SAEs
TABLE 12 The SAEs and ARs reported by patients and practices during the 2-year trial period and emergency
hospitalisations from HES data
SAEs, hospital admissions and ARs
Open practices Blind practices
TotalOC OD BC BD
SAEs
Number of SAEs
None reported 408 359 347 349 1463
1 reported 13 43 37 36 129
2 reported 0 3 6 8 17
3 reported 0 1 1 1 3
4 reported 0 1 1 1 3
Total 421 407 392 395 1615
Reporting ≥ 1 SAE, n (%) 13 (3.1) 48 (11.8) 45 (11.5) 46 (11.7) 152 (9.4)
Reporting ≥ 1 life-threatening SAE, n (%) 6 (1.4) 10 (2.5) 7 (1.8) 11 (2.8) 34 (2.1)
Participants with ≥ 1 SAE resulting in disability, n (%) 3 (0.7) 8 (2.0) 2 (0.5) 3 (0.8) 16 (1.0)
Participants with ≥ 1 SAE not defined as cancer or
resulting in death or hospitalisation,a n (%)
0 (0.0) 0 (0.0) 2 (0.5) 3 (0.8) 5 (0.3)
Reporting ≥ 1 SAE requiring hospitalisation, n (%) 7 (1.7) 43 (10.6) 40 (10.2) 41 (10.4) 131 (8.1)
Source of notification for participants with non-fatal SAEs
Quarterly follow-up NA 31 35 35 101
GP practice during trial 0 3 4 4 11
At 2-year follow-up 7 5 2 1 15
Hospital admissions from HES data44
Reporting ≥ 1 SAE requiring hospitalisation, n (%) 52 (12.4) 47 (11.5) 44 (11.2) 48 (12.2) 191 (11.8)
ARs
Participants reporting ARs to study oil,b n (%) NA 12 (2.9) 4 (1.0) 5 (1.3) 21 (1.8)
Possible 6 2 2 10
Probable 2 2 1 5
Definite 0 0 1 1
Not assessable 4 0 1 5
NA, not applicable.
a These would not be known via HES or cancer/death registration.
b ARs include five participants with diarrhoea, four with nausea, four with skin reactions and eight with other symptoms.
The AR that was definitely related was ‘bad taste in the mouth’. The probably related ARs were two participants
reporting diarrhoea, two reporting nausea and one with skin rash.
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(8.7%), and none in OCs. ARs were rare, with a non-significantly higher rate on OD (2.9%) than on BD
(1.1%) (Wilcoxon signed-rank test; p = 0.13). Neither SAEs nor ARs were significantly related to treatment in
blind practices.
Quality of life
The self-assessed QoL score at baseline decreased with age, as expected (see lifestyle questionnaire in
Appendix 1). At baseline, 23.9% of individuals reported problems with mobility, 3.1% reported problems
with self-care, 11.1% reported problems performing usual activities, 41.4% reported some pain and
12.5% reported some anxiety or depression. Overall, 49% of individuals reported no problems with
mobility, self-care or performing usual activities and did not report pain, discomfort, anxiety or depression
(Table 13). The lowest QoL scores (reflecting some trouble with four or five of the indicators or extreme
trouble with two or more indicators) were reported by 4% of the population overall, but this varied by GP
practice (0–17%).
Serum 25(OH)D concentrations
Blood samples valid for 25(OH)D analysis were collected for 1608 participants at baseline and 1448
participants at the year 2 visit. (Four baseline samples were not received at the laboratory and three were
insufficient.) Overall, 82.6% of participants had baseline 25(OH)D below the 75 nmol/l threshold. Baseline
levels by demographic and lifestyle factors reported at baseline are shown in Table 14. Levels decreased with
increasing age [p(trend) = 0.01] and were lower in women (p < 0.0001). Average levels were highest in
summer and autumn, lower in winter and even lower in spring (p < 0.0001) and increased with skin darkness
from the fairest skin to participants who reported that they rarely burn and always tan (olive skin) (p < 0.0001).
The small number of participants who described their skin colour as brown or black had lower levels than
those with olive skin. Average levels increased with frequency of eating oily fish, although the mean level of
66 nmol/l in participants who reported eating oily fish more than four times a week was still below the
adequacy threshold of 75 nmol/l. Levels were lower in participants living at higher latitude (p = 0.03 adjusted
for IDAOPI deprivation score). The three right-hand columns in Table 14 show adjusted means and
significance levels from a multiple regression including all variables in the table. The trend of reduced 25(OH)
D with increasing age was virtually eliminated after adjustment for all variables [p(trend) 0.01 unadjusted,
0.6 adjusted]. The magnitude and significance of trends for other variables were slightly weakened or
unaffected by adjustment.
TABLE 13 Self-assessed QoL at baseline by age
QoL score, n (%)
Age (years)
Total65–69 70–74 75–79 80–84
5 (best health) 349 (55.9) 252 (49.4) 131 (40.3) 56 (35.9) 788 (48.8)
6 157 (25.2) 126 (24.7) 90 (27.7) 44 (28.2) 417 (25.8)
7 73 (11.7) 82 (16.1) 59 (18.2) 21 (13.5) 235 (14.6)
8 27 (4.3) 29 (5.7) 34 (10.5) 23 (14.7) 113 (7.0)
≥ 9 (worst health) 18 (2.9) 21 (4.1) 11 (3.4) 12 (7.7) 62 (3.8)
Total 624 (100) 510 (100) 325 (100) 156 (100) 1615 (100)
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TABLE 14 Baseline blood 25(OH)D levels (nmol/l) and baseline questionnaire items in 1608 trial participants with baseline blood samples. Adjusted means were estimated in a
multivariate regression including all variables in the table
Demographic and lifestyle
factors
Univariate analysis Multivariate regression
n Mean
25th
percentile Median
75th
percentile
Unadjusted
p-value
Adjusted
mean 95% CI
Adjusted
p-valuea
Male 852 54.2 33.7 50.3 69.5 < 0.001 53.2 51.6 to 54.9 0.003
Female 756 48.5 29.1 44.3 64.3 49.6 47.8 to 51.3
Blind practices 781 50.2 29.9 45.9 64.4 0.07 50.1 48.2 to 52.0 0.06
Open practices 827 52.7 32.3 48.6 68.8 52.9 51.0 to 54.7
Season recruited
Summer (June–August) 495 59.5 39.9 56.2 75.1 < 0.001 58.1 55.9 to 60.2 < 0.001
Autumn (September–November) 244 58.0 41.0 56.4 71.7 56.4 53.4 to 59.5
Winter (December–February) 257 47.1 28.0 42.7 62.3 50.5 47.5 to 53.6
Spring (March–May) 612 44.3 25.0 39.9 56.7 44.7 42.8 to 46.6
Complexion
Very fair 80 39.4 22.3 37.9 52.1 < 0.001 49.3 43.8 to 54.7 0.001
Fair 279 46.8 28.0 41.6 62.5 49.1 46.2 to 52.0
Pale 397 48.0 29.5 45.6 62.6 47.9 45.5 to 50.3
Olive 805 56.2 36.1 52.8 71.3 54.4 52.7 to 56.1
Brown/black 45 49.0 22.5 41.8 59.7 51.2 44.1 to 58.2
Eating oily fish
Less than once per week 598 48.7 27.3 44.5 64.3 < 0.001 49.7 47.7 to 51.6 0.001
Once per week 599 52.1 33.3 47.3 67.1 51.3 49.3 to 53.2
2 or 3 times per week 382 53.9 34.4 50.6 69.1 53.8 51.4 to 56.2
≥ 4 times per week 29 65.9 36.6 59.8 82.1 64.1 55.2 to 72.9
Travel abroad in previous year
No 704 44.3 25.6 40.9 58.8 < 0.001 46.8 45.0 to 48.7 < 0.001
Yes 902 57.2 37.3 53.1 72.4 55.2 53.6 to 56.8
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Demographic and lifestyle
factors
Univariate analysis Multivariate regression
n Mean
25th
percentile Median
75th
percentile
Unadjusted
p-value
Adjusted
mean 95% CI
Adjusted
p-valuea
QoL score
5 (best) 785 55.6 36.5 51.6 70.1 < 0.001 53.7 52.0 to 55.5 < 0.001
6 414 51.6 30.8 46.9 67.9 51.4 49.0 to 53.7
7 235 44.4 24.6 38.6 60.9 47.0 43.9 to 50.2
≥ 8 (poorest) 174 42.5 24.3 38.7 56.2 47.8 44.1 to 51.5
Age (years)
65–69 621 53.2 35.0 49.8 67.9 0.013 51.5 49.6 to 53.4 0.6
70–74 509 51.9 30.8 47.6 66.4 52.2 50.1 to 54.3
75–79 324 49.5 28.3 43.7 65.3 50.9 48.3 to 53.6
80–84 154 47.7 25.7 43.3 67.2 50.3 46.5 to 54.2
Latitude
51° 878 53.8 32.2 49.7 69.4 < 0.001 53.8 52.2 to 55.4 < 0.001
52° 220 48.8 29.6 44.4 63.5 50.6 47.0 to 54.2
54° 427 49.5 31.6 46.0 65.4 47.5 45.0 to 49.9
55° 83 44.7 22.8 42.2 55.4 50.5 45.0 to 55.9
Quintile deprivation score
1 (lowest) 91 39.1 19.9 32.4 51.7 < 0.001 47.3 42.2 to 52.4 0.04
2 137 47.7 29.1 43.1 63.7 48.2 44.1 to 52.3
3 289 53.3 34.1 50.4 67.9 51.8 49.0 to 54.6
4 431 52.0 31.1 47.4 68.3 52.3 50.0 to 54.6
5 (highest) 660 52.9 32.5 48.6 67.6 52.2 50.3 to 54.0
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TABLE 14 Baseline blood 25(OH)D levels (nmol/l) and baseline questionnaire items in 1608 trial participants with baseline blood samples. Adjusted means were estimated in a
multivariate regression including all variables in the table (continued )
Demographic and lifestyle
factors
Univariate analysis Multivariate regression
n Mean
25th
percentile Median
75th
percentile
Unadjusted
p-value
Adjusted
mean 95% CI
Adjusted
p-valuea
Time spent outdoors per day (hours)
< 1 309 37.6 23.0 33.3 48.4 < 0.001 42.1 39.2 to 44.9 < 0.001
1–2 543 48.8 29.6 45.6 64.0 49.9 47.9 to 52.0
3–4 332 54.5 34.7 50.6 69.3 53.3 50.7 to 55.9
≥ 4 422 62.8 42.3 59.7 78.8 59.0 56.7 to 61.4
Use sun protection
Never 192 50.4 29.8 43.4 64.1 0.3 51.0 47.5 to 54.6 0.3
Rarely 143 49.7 30.2 44.1 63.0 49.5 45.5 to 53.6
Sometimes 392 51.5 32.4 48.3 67.5 51.1 48.6 to 53.5
Often 879 52.1 30.9 48.0 67.8 52.1 50.5 to 53.8
Actively seek suntan
Never 1006 47.9 28.6 43.5 62.8 < 0.001 48.6 47.1 to 50.2 < 0.001
Rarely 242 50.6 32.2 49.1 65.3 51.0 48.0 to 54.1
Sometimes 215 58.9 38.6 52.6 74.3 58.0 54.7 to 61.2
Often 143 67.4 46.3 63.0 83.2 62.8 58.7 to 66.8
Sunbed use in past year
Never 1592 51.4 30.9 47.1 66.4 0.009 51.4 50.2 to 52.6 0.02
1–9 times 10 65.8 48.6 68.1 79.1 59.9 44.9 to 74.9
≥ 10 times 4 79.1 51.2 80.1 107.0 76.7 52.9 to 100.5
CI, confidence interval.
a For all ordinal variables, p-values for trends are given.
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Treatment effects
Figure 6 and Table 15 show blood 25(OH)D levels at baseline and at 2 years in control participants and in
those randomised to receive vitamin D. The mean blood 25(OH)D levels at follow-up were 109.6 nmol/l
in those allocated to vitamin D and 51.8 nmol/l in control participants. The proportion ≥ 75 nmol/l was
16.4% at baseline and 88.0% at 2 years in the vitamin D treatment arms but remained unchanged in the
control arms (18.3% at baseline, 17.9% at 2 years). The proportion ≥ 75 nmol/l at 2 years was 51.7%
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FIGURE 6 Baseline blood 25(OH)D levels by treatment arm at (a) baseline and (b) 2 years. The vertical line shows
the suboptimal 75 nmol/l threshold.
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TABLE 15 Blood 25(OH)D levels at baseline (n= 1608) and follow-up (n= 1448)
Blood 25(OH)D (nmol/l)
Open practices, n (%) Blind practices, n (%)
OC OD BC BD
Baseline
0–24 65 (15.4) 66 (16.3) 71 (18.3) 56 (14.3)
25–49 153 (36.3) 147 (36.2) 146 (37.5) 166 (42.4)
50–74 126 (29.9) 120 (29.6) 101 (26.0) 112 (28.6)
75–99 56 (13.3) 51 (12.6) 48 (12.3) 36 (9.2)
100–149 19 (4.5) 21 (5.2) 21 (5.4) 21 (5.4)
≥ 150 2 (0.5) 1 (0.3) 2 (0.5) 1 (0.3)
All participants
< 75 344 (81.7) 333 (82.0) 318 (81.8) 334 (85.2)
≥ 75 77 (18.3) 73 (18.0) 71 (18.3) 58 (14.8)
Total participants 421 (100.0) 406 (100.0) 389 (100.0) 392 (100.0)
2-year visit
0–24 50 (13.7) 0 (0.0) 67 (18.5) 1 (0.3)
25–49 130 (35.7) 6 (1.6) 134 (37.0) 5 (1.4)
50–74 115 (31.6) 42 (11.4) 100 (27.6) 33 (9.4)
75–99 57 (15.7) 106 (28.7) 38 (10.5) 114 (32.3)
100–149 10 (2.8) 180 (48.8) 20 (5.5) 168 (47.6)
≥ 150 2 (0.6) 35 (9.5) 3 (0.8) 32 (9.1)
All participants
< 75 295 (81.0) 48 (13.0) 301 (83.2) 39 (11.1)
≥ 75 69 (19.0) 321 (87.0) 61 (16.9) 314 (89.0)
Complianta
< 75 43 (12.0) 289 (83.3) 30 (8.9)
≥ 75 314 (88.0) 58 (16.7) 306 (91.1)
Non-compliantb
< 75 5 (41.7) 12 (80.0) 9 (52.9)
≥ 75 7 (58.3) 3 (20.0) 8 (47.1)
Total participants 364 (100.0) 369 (100.0) 362 (100.0) 353 (100.0)
a Still taking study medication at the end of the trial.
b Stopped taking study medication. A 2-year blood sample was not taken for the majority of the participants who stopped
their medication: 31/43 in the OD arm, 26/41 in the BC arm and 36/53 in the BD arm.
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(15/29) in non-compliant participants allocated to vitamin D. Among those allocated to vitamin D, mean
blood levels decreased with time since last dose from 117.6 nmol/l in those tested within a month of last
dose (220 participants) to 108.4 nmol/l in those tested 1–3 months after last dose (463 participants) and
80.0 nmol/l in those tested ≥ 4 months after last dose (38 participants).
Figure 7 shows that vitamin D levels increased for almost all (99.3%) of those randomised to receive vitamin D.
The estimated mean increase was 57.9 nmol/l (95% CI 56.3 to 59.4 nmol/l) in the vitamin D arms compared
with 0.2 nmol/l (95% CI –1.4 to 1.7 nmol/l) in the control arms. Figure 8 shows the change in each arm and
Figure 9 shows the smaller change in non-compliant (OD and OB) participants who took vitamin D for < 2 years.
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FIGURE 7 Baseline and follow-up blood 25(OH)D levels by allocated treatment arm in 1444 participants who
provided two blood samples. Participants stopping their vitamin D medication early are shown as solid blue points.
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FIGURE 8 Change from baseline to 2 years in blood 25(OH)D levels by treatment arm in 1444 participants who
provided two blood samples. No change is denoted by the vertical line at zero.
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A larger proportion of participants in the control arms had their year 2 visit in winter/spring and baseline visit in
summer/autumn than those in the vitamin D arms (8.7% vs. 6.7%, respectively) (Table 16), so the change in
season was adjusted for yielding an estimated mean increase of 57.8 nmol/l (95% CI 56.1 to 59.5 nmol/l) in
the vitamin D arms compared with 0.3 nmol/l (95% CI –1.4 to 2.0 nmol/l) in the control arms. In the control
arms, the effect of season change was fairly small with an estimated increase of 5.7 nmol/l (95% CI 3.0 to
8.3 nmol/l) for those whose baseline blood was taken in winter/spring and follow-up was taken in summer/
autumn. Conversely, the estimated decrease in vitamin D levels in control participants whose blood samples
were taken in summer/autumn at baseline and winter/spring at follow-up was 8.8 nmol/l (95% CI 4.9 to
12.6 nmol/l).
Table 17 shows significantly lower blood 25(OH)D levels at baseline in all participants and at follow-up
among control participants who did not take supplements containing vitamin D (p < 0.0001). The mean
blood 25(OH)D (nmol/l) was 47.0 (95% CI 45.5 to 48.5) among those not taking supplements compared
with 65.5 (95% CI 62.8 to 68.1) among those taking supplements at baseline, and similar results were
seen at follow-up among the control participants. However, this higher level was still below the optimal
threshold of 75 nmol/l. Additional supplementation did not change the blood 25(OH)D levels among those
randomised to take vitamin D.
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FIGURE 9 Change in blood 25(OH)D levels in those allocated to take vitamin D who were compliant and those who
stopped taking their medication (non-compliant, n= 41).
TABLE 16 Change in season between baseline and follow-up visit for those with two blood samples (n= 1444)
Season change between visits Control Vitamin D Total
Summer/autumn to winter/spring, n (%) 154 (21.3) 144 (20.0) 298 (20.6)
Same season, n (%) 507 (70.0) 528 (73.3) 1035 (71.7)
Winter/spring to summer/autumn, n (%) 63 (8.7) 48 (6.7) 111 (7.7)
Total 724 720 1444
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TABLE 17 Blood 25(OH)D levels at baseline and follow-up in relation to daily vitamin D from all supplements being
taken at baseline and at the 2-year visit (combined data from self-report and GP records – doses from GP notes as
defined in Table 11)
Daily vitamin D
supplements n < 75 nmol/l, n (%) Mean 25th percentile Median 75th percentile
Baseline
None 1218 1055 (86.6) 47.0 28.4 42.4 61.4
≤ 400 IU 381 268 (70.3) 65.3 47.8 61.2 79.3
> 400 IU 9 6 (66.7) 71.5 52.8 66.1 81.7
Total 1608 1329 (82.6) 51.5 30.9 47.4 66.6
Follow-up visit
OC
None 278 234 (84.2) 49.3 30.5 46.5 62.3
≤ 400 IU 67 49 (73.1) 64.1 48.6 64.1 78.7
> 400 IU 19 12 (63.2) 68.3 50.6 65.2 80.9
Total 364 295 (81.0) 53.0 34.1 50.6 68.4
OD
None 304 44 (14.5) 108.1 83.7 107.2 126.4
≤ 400 IU 58 3 (5.2) 121.6 96.2 116.0 132.6
> 400 IU 7 1 (14.3) 99.1 79.2 80.6 120.0
Total 369 48 (13.0) 110.0 85.3 108.5 127.0
BC
None 298 256 (85.9) 46.6 26.4 42.5 62.9
≤ 400 IU 50 36 (72.0) 68.7 47.7 59.8 77.0
> 400 IU 14 9 (64.3) 71.6 62.2 68.0 87.3
Total 362 301 (83.1) 50.6 29.4 46.3 67.2
BD
None 284 32 (11.3) 108.3 86.9 105.3 124.2
≤ 400 IU 60 7 (11.7) 113.6 91.9 103.3 128.4
> 400 IU 9 0 (0.0) 106.2 102.9 106.5 111.4
Total 353 39 (11.0) 109.2 88.6 104.9 123.7
All control participants
None 576 490 (85.1) 47.9 28.3 44.7 62.6
≤ 400 IU 117 85 (72.7) 66.1 48.6 62.0 77.0
> 400 IU 33 21 (63.6) 69.7 61.1 67.4 84.1
Total 726 596 (82.1) 51.8 32.0 48.2 67.3
All allocated to vitamin D
None 588 76 (12.9) 108.2 85.7 106.5 125.7
≤ 400 IU 118 10 (8.5) 117.5 92.9 109.9 132.6
> 400 IU 16 1 (6.3) 103.1 81.8 103.0 115.7
Total 722 87 (12.0) 109.6 87.4 107.0 126.1
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Tables 18 and 19 show the number of infections during the 2-year trial period as reported from GP
notes for all patients, comparing control participants (untreated or placebo) with vitamin D participants
(open-label or blind). The overall number of infections during the 2-year trial period did not differ between
control and vitamin D arms (see Table 19): 28.0% of those in the control arms had at least one infection
compared with 26.8% in the vitamin D arms. A slightly higher proportion of control participants with low
blood 25(OH)D had at least one infection during the trial period compared with those allocated vitamin D
(31.6% vs. 25.9% in the < 25 nmol/l group and 29.1% vs. 28.4% in the 25–49 nmol/l group).
There were no significant differences between the treatment arms in changes from baseline to follow-up
for systolic BP and BMI (Table 20). A small increase in diastolic BP and a small decrease in health score
were seen among those allocated to take vitamin D (p = 0.03 and p = 0.04, respectively). No significant
differences were seen between the treatment arms regarding changes in the five indices of QoL (Table 21).
On average, participants lost 0.47 cm in height and 0.55 kg in weight over the 2 years of the trial.
TABLE 18 Number of infections during the 2-year trial period in GP records
Type of infection
Number of infections in 2 years, n (%)
Total0 1 2 3 ≥ 4
All infections
Control 585 (72.0) 145 (17.8) 48 (5.9) 18 (2.2) 17 (2.1) 813
Vitamin D 587 (73.2) 142 (17.7) 49 (6.1) 14 (1.7) 10 (1.2) 802
Upper respiratory infections
Control 753 (92.6) 57 (7.0) 2 (0.2) 1 (0.1) 0 (0.0) 813
Vitamin D 743 (92.6) 53 (6.6) 3 (0.4) 2 (0.2) 1 (0.1) 802
Lower respiratory infections
Control 735 (90.4) 57 (7.0) 17 (2.1) 3 (0.4) 1 (0.1) 813
Vitamin D 733 (91.4) 53 (6.6) 11 (1.4) 2 (0.2) 3 (0.4) 802
Urinary tract infections
Control 772 (95.0) 27 (3.3) 9 (1.1) 1 (0.1) 4 (0.5) 813
Vitamin D 774 (96.5) 25 (3.1) 2 (0.2) 0 (0.0) 1 (0.1) 802
Skin/mucosal or soft tissue infections
Control 744 (91.5) 54 (6.6) 8 (1.0) 7 (0.9) 0 (0.0) 813
Vitamin D 738 (92.0) 51 (6.4) 10 (1.2) 1 (0.1) 2 (0.2) 802
Other infections
Control 770 (94.7) 36 (4.4) 6 (0.7) 1 (0.1) 0 (0.0) 813
Vitamin D 761 (94.9) 35 (4.4) 6 (0.7) 0 (0.0) 0 (0.0) 802
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TABLE 19 Number of infections during the 2-year trial period by baseline blood 25(OH)D
Type of infection Arm
Baseline blood 25(OH)D (nmol/l), n (%)
Total,
n (%)< 25 25–49 50–74 ≥ 75
Any infections
At least one infection Control 43 (31.6) 87 (29.1) 60 (26.4) 37 (25.0) 227 (28.0)
Vitamin D 35 (25.7) 85 (28.4) 61 (26.9) 33 (22.3) 214 (26.4)
At least two infections Control 23 (18.9) 27 (8.6) 23 (9.9) 10 (7.6) 83 (10.4)
Vitamin D 12 (9.8) 33 (10.5) 19 (8.2) 9 (6.9) 73 (9.1)
Upper respiratory infections
At least one infection Control 10 (7.4) 20 (6.7) 15 (6.6) 15 (10.1) 60 (7.4)
Vitamin D 8 (5.9) 21 (7.0) 19 (8.4) 10 (6.8) 58 (7.2)
At least two infections Control 1 (0.8) 0 (0.0) 1 (0.4) 1 (0.8) 3 (0.4)
Vitamin D 2 (1.6) 1 (0.3) 3 (1.3) 0 (0.0) 6 (0.8)
Lower respiratory infections
At least one infection Control 18 (13.2) 28 (9.4) 23 (10.1) 9 (6.1) 78 (9.6)
Vitamin D 13 (9.6) 31 (10.4) 19 (8.4) 6 (4.1) 69 (8.5)
At least two infections Control 5 (4.1) 6 (1.9) 9 (3.9) 1 (0.8) 21 (2.6)
Vitamin D 5 (4.1) 6 (1.9) 4 (1.7) 1 (0.8) 16 (2.0)
Urinary tract infections
At least one infection Control 12 (8.8) 13 (4.3) 9 (4.0) 6 (4.1) 40 (4.9)
Vitamin D 5 (3.7) 10 (3.3) 8 (3.5) 5 (3.4) 28 (3.5)
At least two infections Control 5 (4.1) 4 (1.3) 3 (1.3) 2 (1.5) 14 (1.8)
Vitamin D 0 (0.0) 3 (1.0) 0 (0.0) 0 (0.0) 3 (0.4)
Skin/mucosal or soft tissue infections
At least one infection Control 16 (11.8) 27 (9.0) 18 (7.9) 8 (5.4) 69 (8.5)
Vitamin D 14 (10.3) 24 (8.0) 18 (7.9) 8 (5.4) 64 (7.9)
At least two infections Control 4 (3.3) 6 (1.9) 4 (1.7) 1 (0.8) 15 (1.9)
Vitamin D 3 (2.5) 5 (1.6) 2 (0.9) 3 (2.3) 13 (1.6)
Other infections
At least one infection Control 7 (5.1) 18 (6.0) 10 (4.4) 8 (5.4) 43 (5.3)
Vitamin D 5 (3.7) 17 (5.7) 11 (4.8) 8 (5.4) 41 (5.1)
At least two infections Control 3 (2.5) 3 (1.0) 1 (0.4) 0 (0.0) 7 (0.9)
Vitamin D 0 (0.0) 3 (1.0) 2 (0.9) 1 (0.8) 6 (0.8)
Participants, n
Control 136 299 227 148 810
Vitamin D 122 313 232 131 798
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Table 22 shows the number of GP appointments recorded in the GP notes during the year before randomisation
and during the 2-year trial period. There was a mean of 5.7 appointments in the year preceding randomisation
with no significant differences between the treatment arms (i.e. 5.5 appointments in the OC arm, 5.4 in the OD
arm and 5.9 in both blind treatment arms). The mean number of appointments per year increased to 6.3 during
the trial, with no significant differences either between year 1 and year 2 or between treatment arms.
TABLE 20 Blood pressure, height, weight, BMI and health score at baseline and follow-up
Health measures
Control
(n= 732)
Vitamin D
(n= 726)
Treatment
difference 95% CI p-value
Change in systolic BP (mmHg) 0.14 1.21 1.07 –0.75 to 2.88 0.2
Change in diastolic BP (mmHg) –0.55 0.63 1.19 0.11 to 2.26 0.03
Change in height (cm) –0.46 –0.48 –0.02 –0.26 to 0.22 0.9
Change in weight (kg) –0.70 –0.39 0.31 –0.19 to 0.81 0.2
Change in BMI (kg/m2) –0.10 0.01 0.10 –0.09 to 0.30 0.3
Change in health score (out of 100) 0.33 –1.12 –1.45 –2.82 to –0.08 0.04
TABLE 21 Changes in health state as measured using the QoL questionnaire
QoL indices
Experiencing changes in health state, n (%)
Control Vitamin D
N (%) Worsened Improved N (%) Worsened Improved
Mobility
No problem at baseline 560 (76.6) 82 (14.6) NA 575 (79.1) 91 (15.8) NA
Problems at baseline 171 (23.4) 0 52 (30.4) 152 (20.9) 0 50 (32.9)
Self-care
No problem at baseline 712 (97.4) 17 (2.4) NA 704 (96.8) 15 (2.1) NA
Problems at baseline 19 (2.6) 0 8 (42.1) 23 (3.2) 1 (4.3) 10 (43.5)
Usual activities
No problem at baseline 644 (88.1) 69 (10.7) NA 665 (91.5) 63 (9.5) NA
Problems at baseline 87 (11.9) 2 (2.3) 42 (48.3) 62 (8.5) 2 (3.2) 33 (53.2)
Pain/discomfort
No problem at baseline 438 (59.9) 115 (26.3) NA 438 (60.2) 135 (30.8) NA
Problems at baseline 293 (40.1) 15 (5.1) 104 (35.5) 289 (39.8) 12 (4.2) 99 (34.3)
Anxiety/depression
No problem at baseline 654 (89.5) 71 (10.9) NA 628 (86.4) 59 (9.4) NA
Problems at baseline 77 (10.5) 6 (7.8) 33 (42.9) 99 (13.6) 3 (3.0) 43 (43.4)
NA, not applicable.
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TABLE 22 Number of GP appointments in the year prior to randomisation and during the 2-year trial period from
GP records
Number of GP appointments
Open practices, n (%) Blind practices, n (%)
Total, n (%)OC OD BC BD
Total participants 421 407 392 395 1615
No dataa 20 21 8 12 61
1 year prior to randomisation
0–5 appointments 218 (54.4) 208 (53.9) 195 (50.8) 189 (49.4) 810 (52.1)
5–9 appointments 112 (27.9) 108 (28.0) 117 (30.5) 110 (28.7) 447 (28.8)
10–14 appointments 45 (11.2) 45 (11.7) 42 (10.9) 56 (14.6) 188 (12.1)
≥ 15 appointments 26 (6.5) 25 (6.5) 30 (7.8) 28 (7.3) 109 (7.0)
Mean 5.5 5.4 5.9 5.9 5.7
Median 4 4 4 5 4
Year 1 of trial
0–5 appointments 194 (48.4) 176 (45.6) 193 (50.3) 198 (51.7) 761 (49.0)
5–9 appointments 122 (30.4) 114 (29.5) 104 (27.1) 117 (30.6) 457 (29.4)
10–14 appointments 53 (13.2) 66 (17.1) 52 (13.5) 39 (10.2) 210 (13.5)
≥ 15 appointments 32 (8.0) 30 (7.8) 35 (9.1) 29 (7.6) 126 (8.1)
Mean 6.4 6.5 6.4 5.8 6.3
Median 5 5 4 4 5
Year 2 of trial
0–5 appointments 195 (48.6) 190 (49.2) 186 (48.4) 184 (48.0) 755 (48.6)
5–9 appointments 109 (27.2) 115 (29.8) 121 (31.5) 115 (30.0) 460 (29.6)
10–14 appointments 63 (15.7) 51 (13.2) 36 (9.4) 51 (13.3) 201 (12.9)
≥ 15 appointments 34 (8.5) 30 (7.8) 41 (10.7) 33 (8.6) 138 (8.9)
Mean 6.5 6.1 6.5 6.4 6.4
Median 5 5 5 5 5
2-year trial period
0–5 appointments 93 (23.2) 83 (21.5) 92 (24.0) 94 (24.5) 362 (23.3)
5–9 appointments 98 (24.4) 89 (23.1) 100 (26.0) 101 (26.4) 388 (25.0)
10–14 appointments 74 (18.5) 81 (21.0) 73 (19.0) 75 (19.6) 303 (19.5)
15–19 appointments 56 (14.0) 53 (13.7) 49 (12.8) 40 (10.4) 198 (12.7)
≥ 20 appointments 80 (20.0) 80 (20.7) 70 (18.2) 73 (19.1) 303 (19.5)
Mean 12.9 12.6 12.9 12.2 12.6
Median 10 11 9.5 9 10
a No data; participants’ records not available from the GP practice, including removal because of death or moving from
the area.
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Table 23 shows the mortality and cancer incidence for the 1615 participants in the trial. All were flagged
with NHS Digital, providing complete follow-up data. The overall death rate was 4.2% in the vitamin D
treatment arms and 2.8% in the untreated control arms (p = 0.12), with a cancer incidence rate over
2 years of 2.6% in those allocated to vitamin D and 3.1% among those allocated to the control arms
(p = 0.6). Cause of death is shown in the lower part of the table. This is not yet available for the most
recent deaths (5/57).
TABLE 23 Mortality, cancer incidence and cause of death by treatment allocation
Follow-up OC, n (%) OD, n (%) BC, n (%) BD, n (%) Total, n (%)
Total participants 421 (100) 407 (100) 392 (100) 395 (100) 1615 (100)
Alive at follow-upa 408 (96.9) 389 (95.5) 382 (97.4) 379 (96.0) 1158 (96.5)
Died within 2 years of randomisation 4 (1.0) 8 (2.0) 3 (0.8) 5 (1.3) 20 (1.2)
Died between 2 and 4 years after
randomisation
9 (2.1) 10 (2.5) 7 (1.8) 11 (2.8) 37 (2.3)
Total deaths 13 (3.1) 18 (4.4) 10 (2.6) 16 (4.1) 57 (3.5)
Cancer incidence within 2 years of
randomisation
15 (3.6) 12 (3.0) 10 (2.6) 9 (2.3) 46 (2.8)
Control, n (%) Vitamin D, n (%)
Total participants 813 (100) 802 (100)
Cause of death
Cancer 5 (0.62) 14 (1.75)
Circulatory 7 (0.86) 12 (1.50)
Other 8 (0.98) 6 (0.75)
Not known 3 (0.37) 2 (0.25)
Total deaths 23 (2.83) 34 (4.24)
a Mortality follow-up until February 2018, approximately 4 years after the last patient was randomised.
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Chapter 4 Discussion
The primary aims of this study were (1) to demonstrate the feasibility of achieving adequate recruitmentthrough GP practices in a larger trial (20,000 participants) of prolonged high-dose vitamin D in people
aged 65–84 years with mortality as the primary outcome and (2) to compare the effects of open and
double-blind randomisation on recruitment, contamination (self-administered or prescribed vitamin D
consumption in control participants) and treatment compliance assessed both by self-report and by blood
25(OH)D concentration at the 2-year final visit, particularly the proportion in whom this figure is < 75 nmol/l.
The proportion of participants with blood 25(OH)D concentration of < 75 nmol/l was 81.8% at baseline,
which confirmed the high prevalence of suboptimal vitamin D status in this age group in the UK. This
decreased to 22.0% at the final 2-year assessment in participants allocated to vitamin D (see Table 15) and
was not significantly altered from baseline in control participants. The only substantial difference between
the protocol in this feasibility study and that proposed for the main trial is the regimen of vitamin D. We
used 100,000 IU monthly, but reports published after we began recruitment suggest that daily dosing is
likely to prove superior.47,48 Therefore, we propose a daily dose of 4000 IU, which was shown to achieve
substantially higher serum 25(OH)D levels than 2000 IU per day in a recent study.49,50
We believe that this is the first such trial in which open-label and double-blind randomisation have been
compared by cluster randomisation. Strong opinions are held on the relative merits and disadvantages of
open-label and blind allocation, and we held divergent views on the best approach for evaluating the
effects of long-term vitamin D on overall mortality. Therefore, we decided that randomised evidence was
needed to inform the choice of protocol for the main trial and that the best way to obtain this was by
cluster randomisation of GP practices between open-label and double-blind randomisation. The 20 GP
practices were situated throughout England in areas ranging from wealthy to relatively deprived.
Preliminary procedures
Study approvals occupied almost 3 years (July 2011–May 2014) before recruitment could begin at all
GP practices. Research Ethics Committee and MHRA approvals were straightforward, and the major delay
was in obtaining approvals for NHS research and development and service support costs in each Clinical
Research Network. In view of this experience, a formal review of the costs and benefits of expediting these
processes for non-commercial population-based trials of this sort might be evaluated in consultation with
the relevant agencies. Protracted correspondence and discussions with NHS Digital also delayed linkage to
HES and other databases to obtain follow-up data for death, cancer registration and hospital admissions.
Our application to NHS Digital underwent 13 revisions for these linkages. A major focus was the wording
of our informed consent, which had been reviewed and approved both by our patient advisory group
and by senior staff at the Health and Social Care Information Centre before the trial began. Requested
amendments included the wording of the London School of Hygiene & Tropical Medicine’s Data Protection
Act registration, and the VIDAL trial website’s description of fair processing, linkage processes, data flow,
research outputs, the target audience and benefits to health and social care.
Recruitment
Recruitment in the pilot practice (practice 0B) began in April 2013 and was completed in September 2013.
Procedures modified over this period included improvements to the web-based clinical data management
system (the VIDAL app, see Appendix 2). The recruitment period in the other 19 practices ranged from
4 to 12 months, and the last participant was randomised in January 2015. Participation was better than
expected, with one in seven (14.2% compared with the protocol target of 9%) of all invited eligible patients
aged 65–84 years being randomised. Despite the matching of practice pairs on region and social deprivation,
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recruitment varied widely within matched pairs (see Table 2), and the slightly higher overall recruitment in
open practices (15.0% of invited patients randomised) than in blind practices (13.4% randomised) did not
approach statistical significance.
Compliance
The proportion of participants allocated to a treatment arm who took all three doses of study medication
was 88.7% in the last 3 months of the trial (see Table 7). The proportion was slightly, but not significantly,
higher for OD participants than for blind participants throughout (see Figure 4), and this non-significant
trend was also seen in the total number of doses taken (see Table 8) and in the proportion of participants
compliant at 6 months who were still taking study medication over the remainder of the trial (see Figure 5).
Feasibility of the main trial
The recruitment target in the VIDAL main trial is 20,000 participants aged 65–84 years with equal numbers
in each 5-year age group (i.e. 200 practices recruiting an average of 100 participants with 25 in each age
group). The recruitment rate was 11.5% at age 80–84 years and higher at < 80 years (see Table 3), so this
uniform age distribution could be achieved if the average number of registered patients aged 80–84 years
in participating practices was 220 and all were invited. The average number of registered patients aged
80–84 years per practice in England is 190, so this should be easily achievable by targeting larger practices.
The proportions of participants choosing e-mail for quarterly follow-up at ages 65–69, 70–74, 75–79
and 80–84 years were 77.4%, 67.6%, 55.7% and 36.5%, respectively (see Table 6). The corresponding
participation rates (see Table 3) imply that in a trial restricted to participants willing to be contacted by e-mail,
the participation rates at ages 65–69, 70–74, 75–79 and 80–84 years would be 10.5%, 11.0%, 7.9% and
4.2%, respectively. To recruit an average of 25 patients in each age group, the following numbers of patients
would need to be invited on average per practice: 240 patients aged 65–69 years; 230 aged 70–74 years;
320 aged 75–79 years; and 600 aged 80–84 years. The average numbers of registered patients per practice in
England in these age groups are 380, 300, 250 and 190, respectively. The main trial could thus be restricted
to participants willing to receive and reply to follow-ups by e-mail for those aged < 75 years, or < 80 years if
larger practices were targeted, but postal contact would be required for many participants aged 80–84 years
to recruit equal numbers in each age range.
A limitation of this study was the virtual absence of recruits of Asian, African or Caribbean origin (see
Table 5). Our protocol for the main trial specifies that practices in areas with large numbers of people from
these ethnic groups should be invited to participate, but we have no information on the participation rate
that could be achieved in such practices.
A further limitation is the monthly dosing regimen, which we would not now recommend. The suggestion
that daily dosing may be clinically more effective than our monthly regimen was published during the
trial.47,48 A feasibility study of daily vitamin D3 supplementation among men and women aged > 65 years
at a GP practice in Oxfordshire (the ‘BEST-D’ study)49,50 showed that allocation to 4000 IU of daily vitamin D
increased 25(OH)D on average by 80 nmol/l and 88% of participants achieved plasma levels of 25(OH)D
> 90 nmol/l. Compliance levels were comparable to those in the current feasibility study, and we would
therefore recommend that daily regimen in the main trial.
Our recruitment, compliance and contamination results are based on patients from the 20 participating
practices and are inevitably limited to the 2-year treatment duration of the trial. We have no direct evidence
of differences between these selected practices and the 200 practices that would be required for the main
trial, or on changes that would occur over the 5-year treatment period of the main trial.
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Contamination in untreated open control participants
Table 11 shows that only 20 (5.0%) of the 400 untreated control participants who were interviewed
at 2 years (366 who attended the 2-year visit and 34 non-attenders who were telephoned) reported
taking > 400 IU of vitamin D per day (11 prescribed and nine self-administered), and only one was taking
> 1000 IU per day. This very low level of self-reported contamination is confirmed by their blood 25(OH)D
levels, which were similar to their baseline results (see Table 15 and Figure 6). Significant contamination
was thus negligible over the 2 years since randomisation, during which time they were not contacted. We
have no reason to think that contamination was much more common among the 17 (4.1% of 417 2-year
survivors allocated to OC) who could not be contacted 2 years after randomisation.
Open versus placebo-controlled trial designs
Compliance and contamination
The only significant difference between BCs and OCs was in the proportion attending the 2-year visit
(94.1% and 87.8%, respectively; p = 0.01), and hence in ‘composite compliance’ (p = 0.01). Contamination
was negligible among open untreated control participants, and treatment compliance was equally high for
those in the OD arm and the blind treatment arms. Any real effect of 5 years of vitamin D on mortality will
thus be estimated with similar power by open or by placebo-controlled randomisation, so the choice
between these trial designs will be determined by other considerations.
Simplicity and cost
The advantages of open allocation with an untreated control arm include simplicity and lower trial costs.
The costs of recruitment are the same for open and blind allocation, and the main additional expenditure
with placebo control would be a doubling of trial office staff costs associated with participant contact and
follow-up during the trial plus the costs of manufacturing, labelling, dispensing and delivering placebo. The
savings that could be achieved in an open trial of 5 years duration might be substantially greater if aspects
of monitoring required for a placebo-controlled trial could be reduced. We have shown that contact with
participants allocated to vitamin D could be conducted entirely by e-mail for those aged < 80 years, with
automated text and/or e-mail reminders to take study medication and report suspected adverse effects.
Those on OD should perhaps be recalled every few years for serum calcium assay, and a sample of a few
hundred in each arm should be recalled at 5 years to confirm the high compliance and low contamination
seen in this trial. However, little useful additional information is obtained by recalling all participants for
a final visit either for the primary aim, the analysis of mortality by allocated treatment, or for cancer
incidence and reasons for hospitalisation, which were captured more completely by linkage with national
databases (cancer registration and HES44). SAEs were reported retrospectively and incompletely by GPs;
96.2% (177/184) of SAEs were deaths or cancer diagnoses or involved hospitalisation (see Table 12). Our
results show that these outcomes will be obtained more completely and reliably by linkage to NHS Digital
databases than by GP or patient report, with no evidence of bias as a result of open randomisation.
Moreover, in the large trial, for which this is a feasibility study, cancer diagnosis and hospitalisation should
be included as primary end points and would therefore not be classed as SAEs. The accumulated evidence
of the safety of high-dose vitamin D will be augmented by other ongoing trials with more detailed clinical
monitoring. The possibility of adverse effects in those allocated to vitamin D can be managed, as in this
trial, by self-report and GPs who are aware that their patient is taking study medication.
Extending treatment beyond 5 years
An important potential advantage of open allocation is that when the trial ends (subject to an application
for extended funding) a further 5-year supply can be offered to participants allocated to vitamin D without
recontacting control participants, provided this is specified at the outset in the patient information. A continued
supply of vitamin D could be offered to those on active treatment following unblinding at the end of a 5-year
double-blind trial, but power might be compromised by increased contamination in those who are informed
that they have been taking placebo for 5 years, and the theoretical advantage of placebo control would be lost
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for the comparison of subsequent mortality. If the effects of vitamin D on mortality are transient and confined
to the period of treatment, as was seen for simvastatin (Zocor©; Merck Serono GmbH, Darmstadt, Germany),51
any effect on long-term mortality would be much larger for ≥10 years than for 5 years of treatment. This
would reinforce the arguments rehearsed earlier (see Chapter 1 Introduction) for the value of a large UK trial.
A trial in which the majority of treated participants continue to take high-dose vitamin D is the only way to
observe the effects of continuing treatment beyond 5 years. Ongoing double-blind trials cannot answer this
important question and, if the effect on mortality is transient, they will also have substantially lower power to
achieve statistical significance. If confirmed, the 4% reduction in overall mortality seen in the VITAL trial (hazard
ratio 2–5 years after entry 0.96, 95% CI 0.84 to 1.11) might justify vitamin D supplementation, but it did not
approach statistical significance.43
The advantages of placebo control are well known. They include unbiased evidence on potential ARs and
on any diagnoses that might be influenced by participants or clinicians knowing that high-dose vitamin D
is being taken. A substantial placebo effect on lifestyle behaviour and hence health is, in principle, possible
if implausible. Many researchers are therefore suspicious of all open trials irrespective of the end point.
Perhaps the strongest reason for insisting on placebo control is the guarantee of universal acceptance of
the results on incidence of non-fatal diseases and, hence, their inclusion in meta-analyses of ongoing trials.
This is reflected in the Cochrane risk-of-bias tool, which downgrades quality of evidence by at least one
step for RCTs when a placebo is not used.
Some co-authors felt a priori that the scientific advantages of a blind design were so great that it should
be replaced by an open design only if it were shown to be substantially (and significantly) inferior in the
cluster randomised comparison of participation, compliance and contamination. That has not happened,
so those co-authors believe that the results reinforce the case for placebo control. Other co-authors think
that an open design is simpler, substantially cheaper and facilitates extending treatment beyond 5 years
and, therefore, believed a priori that the absolute need for a blind design exists only when the primary
outcome is subjective. This group argued that it was only necessary to show that the open design was not
inferior in terms of participation, compliance, non-contamination and retention. This trial has shown the
open design to be essentially equivalent in these areas, so those co-authors believe that the main trial
should use an open design.
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Chapter 5 Conclusions
The study was designed to (1) assess the feasibility of conducting a large trial of vitamin D in healthyadults aged 65–84 years (n = 20,000 with equal numbers aged 65–69, 70–74, 75–79 and 80–84 years)
recruited through 200 GP practices and (2) compare the effects of open-label and placebo-controlled
randomisation on recruitment, compliance and contamination. Our conclusions are therefore restricted
to these issues. The study was not powered to detect clinical effects of vitamin D other than elevation of
blood 25(OH)D, which was the only substantial and statistically significant clinical effect observed.
Recruitment
The overall participation rate (the proportion of invited patients who were randomised) was 14.2% overall
(the protocol target was 9%) and 11.5% at age 80–84 years, with no evidence of a difference between
open and blind practices. This confirms the feasibility of the main trial as planned.
Compliance and contamination
Treatment compliance was high among participants openly allocated to vitamin D and among those on
blind treatment, and contamination was quantitatively negligible in all arms including the open untreated
control arm. A trial of 5 years of treatment would thus be equally powerful whether open or blind,
so the choice of design depends on other considerations.
For the main end points (overall mortality, cancer diagnosis and reasons for hospital admission),
the advantages of open-label randomisation with follow-up by linkage to national registers are:
l A potentially substantial increase in power if those still on medication at 5 years were offered a
continued supply of vitamin D, maintaining a large difference in blood 25(OH)D between treated and
control participants beyond the initial 5 years of the trial. This might not be feasible in a double-blind
trial when treatment is unblinded after 5 years, and in any case results beyond 5 years would not be
placebo controlled.
l A lower cost, as control participants would not be recontacted after randomisation and would not be
given any medication.
The main advantages of placebo control are:
l Reliable evidence on side effects and any potentially subjective outcomes.
l Lifestyle changes that are affected by treatment allocation might in principle influence health, so any
effect observed in an open trial could be a biased estimate of the pharmacological effect of vitamin D.
Research recommendations
1. Having established the feasibility of a large UK vitamin D trial, our main recommendation is that it
should begin as soon as possible, irrespective of the pending results of ongoing trials, which are likely
to be inconclusive for the reasons shown in Table 1 [bolus dosing or daily regimens ≤ 2000 IU, and higher
population 25(OH)D levels than in the UK]. A substantial body of evidence from different populations
will be required to decide whether or not, at what dose and for whom, this mass medication should be
recommended, and results from a UK trial would be the most relevant. Increasing publicity about the
potentially large benefits may make it increasingly difficult to recruit for such a trial. If the evidence from
ongoing trials is encouraging but not strong enough to justify recommending mass medication, or to
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determine both the optimal dose and the blood 25(OH)D level below which it is worthwhile, these issues
may never be satisfactorily resolved.
2. The decision on whether randomisation should be open-label, blind or a mixture of the two in a large
vitamin D trial with mortality as the primary outcome will depend strongly on a priori assumptions.
The NIHR HTA might consider its view on this separately from assessing specific applications to conduct
such a trial.
3. The NIHR HTA in consultation with the relevant agencies might review opportunities for reducing
delays in Clinical Research Network funding approvals for multicentre population-based prophylactic
trials, for simplifying trial regulations for non-prescription treatments, such as vitamin D, for which
extensive evidence on safety is already available, and for arranging linkage to HES and other NHS Digital
databases for all non-commercial medical research.
CONCLUSIONS
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Appendix 1 Lifestyle and quality of life questions
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Appendix 2 The web-based clinical data
management system: the VIDAL online application
The VIDAL app was the web-based clinical data management system developed specifically to streamlinedata capture and management for the VIDAL feasibility study. It was designed to be able to accommodate
the 200 practices and 20,000 participants required for the main trial, to eliminate costly administration,
transport and postal fees, and to optimise the process of data acquisition and data management.
The functions of the VIDAL app were to provide:
l secure online access
l current GP practice and trials office contact details
l access to all current study documents (in the online library)
l access to online CRFs for local GP staff to create, complete and view participant data
l participant accessible follow-up data entry forms (CRFs)
l trials office access to view participant and GP practice data
l participant randomisation into the trial
l online tools for ordering and tracking study medication
l tracking tools for recording blood sample dispatch and receipt
l automated e-mail, text message and telephone call alerts and reminders for participants, GP practices
and trials office staff
l online tools for mail merging and printing study letters and prescriptions and logging reply slips and
consent forms
l reports to monitor participant progress and compliance through the trial
l timely completion of online SAE and AR CRFs.
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